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The phylum Apicomplexa includes many protozoan parasites that cause serious 
human and animal disease, for example Plasmodium, Eimeria and Toxoplasma. 
Treatments against these parasites are limited and novel solutions are urgently 
required. Recently, research has focused on parasite specific features of lipid 
biosynthesis as drug targets. In particular the biosynthesis of sphingolipids, which 
have essential roles in many processes, has been highlighted as a potential target. 
Using the model apicomplexan Toxoplasma gondii we are studying the role of 
parasite and host sphingolipid biosynthesis in invasion and proliferation. Serine 
palmitoyltransferase (SPT) catalyzes the first step in sphingolipid biosynthesis, and 
our results demonstrated that the expression of host cell SPT is unaffected by 
Toxoplasma infection. In mammals the primary complex sphingolipid is 
sphingomyelin (SM), again our data demonstrated that the SM synthases (1 and 2) 
are not influenced by infection. Together these data indicated that parasite 
manipulation of host sphingolipid biosynthesis does not occur, supporting the 
hypothesis that Toxoplasma is dependant on de novo sphingolipid biosynthesis. To 
characterise this pathway, we showed that the Toxoplasma TgSPT1 and 2 are, like 
other eukaryotes, localised and active in the endoplasmic reticulum. However, 
uniquely, they have a prokaryotic origin. Metabolic labelling showed that several 
distinct complex sphingolipids are synthesized independently by the parasite. The 
fungal inositol phosphorylceramide (IPC) synthase inhibitor aureobasidin A (AbA) has 
been reported to target Toxoplasma IPC synthesis. However, our results 
demonstrated that whilst AbA, and an orthologue, are active against the parasite, 
their effect on Toxoplasma de novo sphingolipid biosynthesis is negligible. In 
addition, by using Leishmania major as a model we have analysed the global effect 
of compounds recognised as IPC synthase inhibitors in this kinetoplastid protozoan 
parasite. The results showed that ceramide levels increased in treated parasites, 
perhaps leading to parasite death via secondary signalling dysfunction. These data 




Finally, the anti-leishmanial drug miltefosine showed reduced activity against a 
transgenic strain of L. major lacking sphingolipid biosynthesis ΔLCB2 compared to 
wild type. This suggested the sphingolipid synthesis has a role in sensitivity to the 
drug, metabolomic analyses supported this. 
Taken together, the present findings further characterised the T. gondii sphingolipid 
biosynthetic pathway and indicated the potential to target this in drug discovery 
efforts. In addition, metabolomic and lipidomic approaches confirmed that 
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Chapter One:  
Introduction and Literature Review 
 




1.1 Phylum Apicomplexa 
The protozoan phylum apicomplexa encompasses many unicellular and obligate 
intracellular parasites (Black and Boothroyd, 2000; Blader and Saeij, 2010; 
Graindorge et al., 2016) that are considered a principal source of serious disease in 
humans and cattle (Wasmuth et al., 2009; Hammoudi et al. 2015; Coffey et al., 2016; 
Francia et al., 2016). All of the approximately 5000 species are parasitic (Hu et al. 
2006; Meissner, 2013) and able to proliferate within different host cells, for instance 
lymphocytes, red blood cells, macrophages, muscle tissues, liver cells, intestinal 
epithelial tissues and neuronal cells (Frénal and Soldati, 2009; Ramakrishnan et al., 
2015). For example, infection with Plasmodium species, the causative agent of 
malaria, leads to roughly 216 million cases in all over the world, and 445.000 death 
cases, 90% of them in Africa (Alonso and Noor, 2017)  
Another important apicomplexan parasite is Toxoplasma gondii which causes 
toxoplasmosis or cat litter disease. This parasite infects up to one-third of the human 
population (Flegr, 2013; Sumpf et al., 2017), and is classified by the Center for Disease 
Control and Prevention (CDC) as causing a Neglected Parasitic Infection. Together 
with other coccidian apicomplexans (e.g. Eimeria - coccidiosis) T. gondii also leads to 
a global agricultural loss of >$3 billion per annum (Dalloul and Lillehoj, 2006). These 
parasites are characterized by having an apical complex and many organelles like 
micronemes and rhoptries which play an essential role in the attachment to the host 
cells, invasion (Isaza and Alzate, 2016) and parasitophorous vacuole formation 
(Wasmuth et al., 2009). 
 
1.2 Apicomplexa classification 
This phylum is classified into five major pedigrees according to the phenotypic 
characteristics: Gregarinasina, Piroplasmorida, Haemosporoida, Cryptosporidium 
and Coccidia (Isaza and Alzate, 2016): 
1. Gregarinasina is a subclass includes parasites that infect invertebrate animals 
(Meissner et al., 2013) particularly annelids (Chambouvet et al., 2016) and 
insects (Isaza and Alzate, 2016). However, Chambouvet et al. (2016) found that 
Nematopsis tenporariae, a gregarian parasite belonging to this subclass, infected 




a vertebrate host (frog) by microscopic examination and molecular biology data 
(ribosomal DNA sequencing) of liver cells from the tadpoles of three different 
frog species (Rana temporaria, Rana dalmatina and Hyla arborea).  
2. Piroplasmorida consists of many tick-borne apicomplexan parasites. For 
example: Babesia spp. and Theileria spp. that infect mammals and birds (Lack et 
al, 2012) and cause babesiosis and theileriosis respectively (Isaza and Alzate, 
2016). 
3.  Haemosporoida is an order that includes many important parasites, for instance 
Plasmodium spp. the causative agent of malaria, the king of the diseases.  
4. Cryptosporidium spp. are parasites that cause severe diarrhea in children, 
Cryptosporidium is ranked the second cause of diarrhea in children less than 2 
years after rotavirus in many part of the developing world (Checkley et al., 2015). 
They also cause serious, life-threatening, diseases in immune-deficient and 
organ transplant patients (Hunter and Nicholas, 2002; Vinayak et al., 2015). 
5. Coccidia is a subclass that includes many parasites that cause a serious disease 
in humans and economically important animals (Clark and Black, 2012; Meissner, 
2013). For instance, Neospora, which causes abortion in cattle (Okamoto and 
Kee;ing, 2014), and Toxoplasma gondii, a serious risk in immune-deficient 
patients, especially those with AIDS (Black ad Boothroyd, 2000).  
 
1.3 An Introduction to Toxoplasma gondii 
Toxoplasma is an important apicomplexan parasite which causes toxoplasmosis, 
commonly known as a cat litter disease (Palencia et al., 2017). This genus has only 
one species T. gondii which can infect any nucleated mammalian cells (Frénal and 
Soldati, 2009; Blader and Saeij, 2010; Sher et al., 2016).  
T. gondii was first discovered by scientists at the beginning of the 20th century (Nicolle 
and Manceaux, 1908, 1909; Splendore, 1908 in Dubey, 2009). The genus name is 
derived from the Greek word toxon, meaning “bow” and referring to the crescent 
shape of the organism” (Black and Boothroyd, 2000). T. gondii is used as a model 
apicomplexan parasite for many reasons: availability of many genetic tools (Gubbels 
et al., 2004), ease of laboratory propagation (Kim and Weiss, 2004) due to their ability 




to invade any type of cell (Sher et al., 2016), and it is easy to manipulate its genome 
(Wang et al., 2016). 
T. gondii is an obligate intracellular parasite that has a huge impact on both human 
and animal health. In humans, it causes serious damage to the unborn child 
(congenital toxoplasmosis) (Montoya and Liesenfeld, 2004; Palencia et al., 2017) and 
toxoplasmosis, particularly in immunocompromised patients. In animals, it is the 
important cause of abortion in livestock, and can cause serious economic losses to 
sheep and goat breeders (Coffey et al., 2016). 
In congenital toxoplasmosis acute infection leads, depending on the pregnancy 
period, either to abortion or intellectual retardation (Black and Boothroyd, 2000) for 
instance hydrocephalus, intracranial calcification and chorioretinitis in the fetus 
(Holland, 2003 ; Palencia et al., 2017) (figure 1-1). 











T. gondii is composed of three clonal lineages of differing virulence and 
epidemiology, Type I, II and III (Blader and Saeij, 2010). Type I strains is characterised 
by its ability to grow rapidly in tissue culture, and mostly found in ocular 
toxoplasmosis cases and acute toxoplasmosis, also it found that this strain is highly 
virulent against mice (Grigg et al., 2001). On the other hand, Type II and Type III are 
less virulent in mice and form cysts in vitro (Weiss et al., 2009).  
 
T. gondii have four infective stages in their life cycles (Weiss and Kim, 2007) and 
require intermediate (non-feline) and final (feline) hosts to complete their life cycle 




(Black and Boothroyd, 2000; Blader and Saeij, 2010). The intermediate hosts like 
humans have two stages. Tachyzoites represent the rapidly multiplying stage 
(Montoya and Liesenfield, 2004; Katris et al., 2014). responsible for acute 
toxoplasmosis. The tachyzoite stage is also used for in vitro studies because it is the 
most amenable to experimental work (Weiss and Kim, 2007). The other stage in the 
intermediate host is the slow growing bradyzoite form responsible for chronic 
toxoplasmosis. This stage is converted to tissue cysts to avoid the host immune 
system and establish the toxoplasmosis chronic infection (Weiss and Kim, 2000).   
It is worth mentioning that there is a difference in protein expression in both T. gondii 
tachyzoite and bradyzoite stages, for instance the tachyzoite expresses the following 
surface antigens proteins (SAGs) and surface antigen 1 related sequence proteins 
(SRS): SAG1, SAG2, SAG3, SRS1, SRS2 and SRS3. On the other hand, bradyzoite 
express the following proteins: SAG2C, SAG2X, SRS9 and SAG4 (Mineo et al., 1993). 
The final, feline, hosts also maintain merozoite and sporozoite stages (Weiss and Kim, 
2007). 
T. gondii can cause deleterious effects on the host cell as exemplified in tissue 
damage due to the invasion of the parasite, then parasite proliferation which leads 
to lysis and invasion of new host cells (Hu et al., 2006). T. gondii can infect many 
organs in the body including the brain, spinal cord, eyes, heart, lungs, skin, liver, and 
gastrointestinal tract (CATI, 1997; Del Grande et al., 2017), however the infection is 
mostly asymptomatic in healthy persons because the immune system plays an 
essential role in reducing the parasite’s spread (Black and Boothroyd, 2000) by 
producing interferon gamma (IFN-γ). This is fundamental in innate resistance to T. 
gondii, allowing it to remain dormant as bradyzoites in tissue cysts for the life time 
of the host (Sher et al., 2016). These tissue cysts reside in muscle cells and brain, and 
it has been suggested that there is a relationship between T. gondii chronic infection 
and neurological disorders such as schizophrenia and epilepsy (Fekadu et al., 2010; 
Kamerkar and Davis, 2012). Recent studies showing high level of anti T. gondii IgG 
antibodies in schizophrenia patients when compared to healthy controls (Yolken et 
al., 2009; Pedersen et al., 2012; Del Grande et al., 2017). However, the parasite can 
cause a fatal disease in individuals suffering from immune deficiencies such as AIDS 
(CATI, 1997; Black and Boothroyd, 2000; Hu et al., 2006; William et al., 2012; Palencia 




et al., 2017), as T. gondii can avoid the immune system (Black and Boothroyd, 2000) 
and bradyzoites within tissue cysts can convert to rapidly dividing tachyzoites (Sher 
et al., 2016).  
There are several routes of infection in humans, including eating uncooked infected 
meat and by ingestion of cat faeces from contaminated soil or domestic litter. To 
avoid infection of vulnerable people (e.g. during pregnancy or HIV+) it is 
recommended to cook the meat well, wear gloves when working in the garden, wash 
all fruits and vegetables thoroughly before eating, wash hands carefully after 
handling raw meat, fruit, vegetables and soil, and avoid touching cat faeces (Peters 
et al., 2015; Del Grande et al., 2017). 
 
 1.4 Ultrastructure 
All T. gondii stages are characterized by crescent shape 2-7 µm long (Weiss and Kim, 
2007) (Figure 1-2); structural features include: 
1. A unique anterior cytoskeleton structure called the apical complex (figure 1-2A ; 
1-3) from which the phylum name is derived (Pfluger et al., 2005; Hu et al., 2006). 
This complex is composed of conoid (figure 1-2B), apical rings (figure 1-2C), 
micronemes (figure 1-2D), rhoptries (figure 1-3E), dense granules (figure 1-2F) 
(Morrissette and Sibley, 2002) and subpellicular microtubules (figure 1-2G) 
(Weiss and Kim, 2007; Graindorge et al., 2016).       
2. Organelles derived from endosymbiotic processes, the mitochondria (figure 1-
2H) and apicoplast (figure 1-2I) (van Dooren and Stripen, 2013; Sheiner et al., 
2013; Ngano et al., 2014). The apicoplast is indispensable for apicomplexan 
parasite growth and survival because of its role in the synthesis of many 
important metabolites for instance: heme, fatty acids, isoprenoid and iron 
sulphur synthesis (Fichera and Ross, 1997). 
3. Eukaryotic organelles like a nucleus (figure 1-2J) located close to the cell center, 
the nuclear envelope (figure 1-2K) associated with endoplasmic reticulum (ER) 
(figure 1-2L), and 3-5 Golgi cisternae (Ngo et al., 2000; Weiss and Kim, 2007; 
Sheiner et al., 2013). ER is the organelle where the parasite’s proteins are 
synthesized, then trafficked to the anterior end of the organelle and continue 




their journey to the Golgi apparatus and the specialized organelles (Joiner and 
Roos, 2002). Golgi apparatus is involved in rhoptry biogenesis and also forms the 
inner membrane complex (IMC) (figure 1-2M), a unique structure in T. gondii (Hu 
et al., 2002).    
 
Figure (1-2) T. gondii cell structure (adopted and modified from Baum et al., 2006) 
A: apical complex, B: conoid, C: apical rings, D: micronemes, E: rhoptries, F: dense 
granules, G: subpellicular microtubules, H: mitochondria, I: apicoplast, J: nucleus, 


















1.4.1 Apical complex 
Phylum apicomplexa, including T. gondii is characterized by having a unique apical 
complex (Hu et al., 2006; Shanmugasundram et al., 2012) located at the anterior end 
of the parasite (Morissette and Sibley, 2002; Healsip et al., 2009). This complex plays 
a substantial role in the parasite’s cell division and host cell invasion processes (Shen 


















organelles such as rhoptries, micronemes and dense granules (Blader and Saeij, 
2009). At the anterior tip of this complex is the conoid (Figure 1-3 A).  
 
1.4.2 The conoid 
The conoid is defined as a tube-like structure, consisting of 14 tubulin filaments 
arranged tightly together as a counter clockwise spiral (Morissette and Sibley, 2002; 
Hu et al., 2002). It is approximately 280 nm long with a diameter of 380 nm (Hu et 
al., 2002). The conoid has more than 170 proteins (Hu et al., 2006). Two of them, 
lysine methyltransferase and ring protein 2 (RNG2), have demonstrated a role in the 
parasite’s motility (Healsip et al., 2011 ; Katris et al., 2014). The conoid is immotile 
and retracted in an intracellular tachyzoite, but extruded and motile in an 
extracellular parasite where it helps the host cell invasion process (Del Carmen et al., 
2009) (Figure 1-3 B). High Ca+2 concentration is thought to be necessary for conoid 
extrusion due to the Ca+2 role in activation of microneme secretion which are play an 
important role in conoid extrusion (Del Carmen et al., 2009). Furthermore, Carey et 
al. (2004) used an inhibitor to block conoid extrusion and found that the parasites 
lost their ability to invade the host cell. However, this inhibitor did not effect motility 
and microneme secretion (Weiss and Kim, 2007).  
Unlike other apicomplexan parasites Plasmodium spp. lack this structure, possibly it 
is not needed as this parasite infects red blood cells easily (Mondragon and Frixione, 
1996). In contrast, T. gondii must penetrate rigorous barriers such as the intestinal 
epithelium cells, and conoid is essential for this. 
 
1.4.3 The micronemes 
Micronemes are secretory organelle located at the apical tip near the conoid 
(Carruthers and Sibley, 1997; Sher et al., 2016). The word microneme is derived from 
the Greek word “small thread”, and their number range between 50 and 100 (Weiss 
and Kim, 2007). These structures secrete many microneme proteins (MICs) (Ngo et 
al., 2000) that are indispensable for the invasion process (Blackman and Carrunthers, 
2013; Coffey et al., 2016). For example, apical membrane antigen 1 (AMA1) orients 
the parasite to the host cell and is involved in invasion (Mital et al., 2005; 




Krishnamurthy et al., 2016) and the formation of the moving junction between the 
parasite and the host (Graindorge et al., 2016). Furthermore, micronemes secrete 
proteins like MIC2, an adhesin regarded an important for motility, and MIC8 which is 
important for rhoptry secretion (Brossier and Sibley, 2005; Giovannini et al., 2011). 
 
1.4.4 The rhoptries 
Rhoptries are club-shaped secretory organelles located at the anterior end of the 
parasite (Coffey et al., 2016; Graindorge et al., 2016). Each parasite has 8-16 rhoptries 
(Porchet-Hernnere et al., 1983 ; Black and Boothroyd, 2000). They secrete rhoptry 
proteins (ROPs) (Ngo et al., 2000) such as ROP16 and ROP18 which both help the 
parasite during the invasion process and are associated with lipids to form 
parasitophorous vacuole membrane (PVM) that segregates the parasite from the 
host cell (Coffey et al., 2016; Sher et al., 2016).  parasitophorous vacuole (PV) is a 
unique compartment found in apicomplexan infection where the parasite can 
salvage the nutrients from the host for their advantage, and it facilitates fast egress 
and dissemination from the host cell (Ngo et al., 2000; Frénal and Soldati, 2009; Katris 
et al., 2014). Suss-Toby et al. (1996) and Blader and Saeij et al. (2010) proposed that 
the PVM lipids are derived only from the host plasma membrane, and there is no 
evidence that there are taken from host intracellular organelles such as the ER, Golgi 
apparatus and lysosome. Importantly, the PV protects the parasite from the external 
environment and gives it the ability to survive and replicate (Sibley et al., 1985; Sher 
et al., 2016).   
 
1.4.5 Dense granules     
These are generally defined as secretory organelles that releases their proteins (GRAs 
such as GRA16 and GRA24) (Ngo et al., 2000) (Graindorge et al., 2016) after PV 
formation (Montoya and Liesenfield, 2004). These proteins are transferred through 
the PVM to the host cell cytoplasm and nucleus (Bougdour et al., 2014) where they 
cause a manipulation of host cell pathways, remodeling them for the benefit of the 
pathogen (Bougdour et al., 2014). 




1.4.6 Polar rings 
These are located beneath the conoid (Figure 1-3 C), and serve as the origin of 
twenty-two subpellicular microtubules (Figure 1-3 D). (Hu et al., 2006) that work as 
the microtubular organizing center and are responsible for the parasite’s shape and 
stability (Black and Boothroyd, 2000; Katris et al., 2014; Wakeman et al., 2014; 
Francia et al., 2016). 
 
1.4.7 Pre-conoidal rings  
This structure surrounds the conoid at the anterior end (Figure 1-3 E). From these 
rings two intraconoidal apical microtubules (Figure 1-3 F) emanate and pass via the 
conoid’s center to end within the body of the cell (Black and Boothroyd, 2000). 
 
1.4.8 Microtubules 
T. gondii has many microtubules indispensable for parasite survival and propagation. 
For instance, twenty-two subpellicular microtubules (Figure 1-3 D). which are 
responsible for parasite’s shape and polarity, emanate from apical polar ring (APR). 
In addition, two intra-conoidal microtubules (Figure 1-3 F) begin in the APR and 
penetrate the conoid ending within the body of the cell. These function as an 
underpinning structure for the secretion of proteins from dense granules, 
micronemes and rhoptries during invasion (Carruthers and Sibley, 1997; Hu et al., 















Figure (1-3) Apical complex (adopted and modified from Liu et al., 2013) 
A: apical complex, B: conoid, C: polar rings, D: subpellicular microtubules, E: pre-


















1.5 Host-parasite interaction 
 T. gondii is regarded as one of the most successful intracellular parasites (including 
viruses, bacteria and fungi) (Roy and Mocarski, 2007) because it can invade any 
nucleated host cell (Graindorge et al., 2016). 
To overcome the negative charge of both parasite and host cell membranes T. gondii 
requires receptor-ligand interactions. The parasite plasma membrane consists of 
from the set of surface antigen proteins (SAGs) predominantly SAG1 (Manger et al., 
1998) which linked by glycosylphosphatidylinositol (GPI) to the membrane, these 
mediate attachments to the host cell (Black and Boothroyd, 2000).   
Several studies demonstrated that the host cell pathways manipulated by the 














analysis). These experiments indicated that the expression of more than 1000 host 
genes involved in fundamental processes (including inflammation, apoptosis, 
metabolism, growth and differentiation) was manipulated (Blader et al., 2001; 
Chaussabel et al., 2003). Blader et al., 2001 stated that these changes belong to one 
of three specific classes: (1) ‘Pro host’ when the host expresses genes required for 
host defense; (2) ‘Pro parasite’ when the host expresses genes required for parasite 
growth; and finally (3) ‘Bystander’ which means that the expressed genes influence 
both host defense and parasite growth.  
As mentioned above, a recent study has shown that after invasion the T. gondii 
manipulates host expression in the nucleus using the dense granule proteins GRA16 
and GRA24 (Coffey et al., 2016). These and other parasite factors manipulate host 
cell gene expression to create an advantageous environment for survival (Bougdour 
et al., 2014), for example by avoiding lysosomal degradation and establishing a safe 
PV.  
T. gondii lytic cycle comprises five stages: the attachment, invasion, PV formation, 
proliferation and egress to infect neighbouring host cell (Black and Boothroyd, 2000). 
To facilitate these processes T. gondii has a unique molecular machinery called the 
glideosome composed of myosin A and gliding associated proteins (GAPs). The 
glideosome is located in the space between the inner membrane complex (IMC) and 
the parasite plasma membrane (PPM) (Soldati, 2008). IMC is a unique structure in T. 
gondii (Frénal and Soldati-Favre, 2009) composed from flattened vesicles located 
between subpellicular microtubules and PPM (Cavalier and Smith, 1991; Graindorge 
et al., 2016), due to the presence of this structure T. gondii and the other 
apicomplexans belong to the class, Alveolata (Cintra and Souza, 1985; Frénal and 
Soldati, 2009). In T. gondii, the glideosome consists of two myosin A heavy and light 
chains in addition two glideosome associated proteins (GAPs) GAP45 and GAP50, all 
of these anchor the glideosome to IMC (Daher and Soldati-Favre, 2009). The 
glideosome function is to translocate the microneme proteins (adhesins) from the 
anterior end to the posterior end of the parasite and to allow it to drive into the host 
cell (Graindorge et al., 2016). In addition, the adhesins play another role, in 
association with proteins such as TgAMA1 (Mital et al., 2005), in the formation of a 
complex (Besteiro et al., 2011) with a group of proteins secreted from an elongated 




section of the rhoptries called the rhoptry neck contains rhoptry neck proteins 
(RONs) (Blader and Saeij, 2010). This complex establishes a tight zone, called the 
moving junction, by which the parasite can enter the host cell (Shen and Sibley, 2012; 
Katries et al., 2014; Graindorge et al., 2016; Krishnamurthy et al., 2016 ). T. gondii 
can then start their journey through the host cell (Frénal and Soldati, 2009).   
Bioinformatic analyses of the parasite genome gave clues on how the parasite 
survives within the host cell by the having the ability to salvage small molecules such 
as glucose, arginine, tryptophan, iron and purine nucleosides. These molecules 
cannot be synthesized by T. gondii de novo pathways but can diffuse through the 
PVM to reach the parasite (Fox et al., 2004). 
Li et al., 2013 found that the parasite salvages some lipid molecules from the host. 
Certain lipids were absent in the extracellular parasite but present in intracellular T. 
gondii, indicating that the parasite salvaged these from the host. 
 
1.6 The Life Cycle of Toxoplasma gondii 
T. gondii needs final and intermediate hosts to complete its life cycle (Black and 
Boothroyd, 2000; Frénal and Sldati, 2009) (figure 1-4). The final, or definitive hosts 
for this parasite are domestic cats and other members of the family Felidae. The 
intermediate hosts are pigs, sheep, birds and rodents. The life cycle begins when cats 
shed unsporulated oocysts (figure 1-4-1) in their faeces which then take from 1-5 
days to sporulate in the environment and become infectious. The intermediate hosts 
(e.g. birds and rodents in nature; pigs and sheep in agriculture) become infected by 
ingesting soil, water or plant materials contaminated with oocysts (which represent 
the infective stage) (Del Grande et al., 2017), after ingestion the oocysts (figure 1-4-
2) transform into the fast dividing tachyzoite stage (Sump et al., 2017), invade the 
host lamina propria and gut epithelium (Frencia et al., 2016), then replicate asexually 
inside the host cell through a unique replication process in T. gondii  called 
endodyogeny (Gubbels et al., 2008). In this process, the mother cell is divided by 
internal budding into two daughter cells (Nishi et al., 2008), the parasites then egress 
from the host cell to infect new cells (Sher et al., 2017). These tachyzoites proliferate 
in many locations, such as neural and muscle tissue, eyes, and the placenta (Many 




and Koren, 2006). Tachyzoites can develop into tissue cyst bradyzoites (figure 1-4-3) 
to protect themselves from the human immune system, these cysts may remain 
throughout the life of the host (Black and Bothroyd, 2000; CDC, 2013). If ingested, 
for example in contaminated meat, the host stomach digests the wall of tissue cyst 
releasing the bradyzoite which is then convert to tachyzoites which can then infect 
most cells (Blader and Saeij, 2010). Definitive hosts, such as domestic cats, become 
infected either by eating intermediate hosts that contain tissue cysts (figure 1-4-4), 
or by ingestion of the sporulated oocysts shed by other Felidae (CDC, 2013; Del 
Grande et al., 2017) (figure 1-4-5).  
Humans, who are end point intermediate hosts (Sher et al., 2016), can be infected 
by (CDC, 2013): 
1. Eating the uncooked meat containing tissue cysts (figure 1-4-6).  
2. Ingestion of foods and water contaminated with cat faeces or via contaminated 
environmental samples (such as fecal-contaminated soil or cat litter boxes) 
(figure 1-4-7).  
3. By blood transfusion or organ transplantation (figure 1-4-8). 




















Figure (1-4) The Life Cycle of Toxoplasma gondii (adopted from Woodhall et al., 
2014) 
1. Oocysts.   2. Oocysts transform into tachyzoites.  3. Tachyzoite localized in 
muscle tissue or neural develop into tissue cyst bradyzoites. 4. Cats may also 
infected by eating intermediate hosts that contain tissue cysts. 5.  Animals can 
become infected by ingesting oocysts. Humans can become infected by many 
ways: 6. By eating raw meat that contains tissue cysts. 7. Eating food or drinking 
water contaminated with cat feces. 8. By blood transfusion or organ 
transplantation. 9. From mother to fetus by via the placenta. Diagnosis is usually 
through serology but T. gondii 10. Can be directly detected in tissue cysts or 11, 















1.7 Diagnosis and treatment of Toxoplasma gondii infection 
Laboratory diagnosis for infection by T. gondii relies on the detection of specific anti-
Toxoplasma immunoglobulins from blood (IgM for recent and IgG for historic 
infections) or PCR from urine samples (Many and Koren, 2006; Calderaro et al., 2009). 
Although it is possible to detect, it is very difficult to treat. 
When T. gondii infects the host, the first response it mediated by macrophages, 
lymphocytes and dendritic cells (Filisetti and Candolfi, 2004). IFN-γ production 
triggers the anti-parasitic activity of macrophages and natural killer cells, including 
the production of reactive oxygen intermediates such as nitric oxide (Lang et al., 
2007). This immune response usually controls the parasite but does not clear the 
infection, however in some circumstances, especially in immunocompromised 
patients and congenitally infected children, infection can cause severe disease. 
Therefore, the need to use drugs to control the infection by T. gondii is clear (Barbosa 
et al., 2012).  
The treatment of apicomplexan parasite infection depends upon chemotherapies 
which target several pathways important in metabolism, for instance folate 
metabolism, hemoglobin digestion and fatty acid biosynthesis (Muller and Hemphil, 
2011). There are several drugs that are used for the treatment of Toxoplasma 
infection, such as sulfonamides and pyrimethamine which both inhibit folate 
metabolism, and spiramycin whose mode of action is unknown (Karimi, 2011; 
Palencia et al., 2017). 
Furthermore, numerous drugs which are used for T. gondii treatment usually depend 
on mode of infection, for instance: spiramycin in case of acute toxoplasmosis in 
pregnant women; a combination of pyrimethamine, sulfadiazine and leucovorin in 
case of infection after 12-18 weeks of gestation; pyrimethamine, sulfadiazine, 
leucovorin and corticosteroid in case of congenital toxoplasmosis infection in the 
infant. Finally, acquired immune deficiency syndrome (AIDS) patients who are 
infected by acute toxoplasmosis can be treated by the following drugs: 
pyrimethamine and sulfadiazine plus leucovorin or clindamycin; trimethoprim; 
leucovorin plus one of the following: clarithromycin, atovaquone, azithromycin or 
dapsone (Montoya and Liesenfeld, 2004).   




 However, these drugs can cause many side effects such as nausea, vomiting, fatigue, 
dizziness, dry mouth, headache, itching, muscle aches and pains (Bihari, 2008). These 
range from acute, thus requiring medical attention, to mild and of little concern. 
Principally they can also lead to treatment non-compliance (Bihari, 2008). For 
example, spiramycin causes gastrointestinal symptoms, sulfonamides are associated 
with neonatal jaundice and pyrimethamine is an antagonist of folic acid and so it is 
generally not recommended for use during pregnancy (Many and Koren, 2006). 
These drugs are effective against the tachyzoite in acute disease, but do no effect the 
encysted bradyzoite stage (Palencia et al., 2017). In addition, combination therapy 
with pyrimethamine and sulfadiazine is associated with multiple toxicity problems 
such as the suppression of bone marrow function and congenital malformations in 
the early stages of pregnancy (Barbosa et al., 2012). Such major side-effects, coupled 
with a lack of efficacy, are regarded as the main causes of failure in the process of 
drug development (Tatonetti et al., 2009; Coppens, 2013).  
Therefore there is need to look for the alternative treatments focusing on parasite 
specific, essential metabolic pathways that are not found in their host. To disrupt 
these parasite pathways, specific small molecule inhibitors of drug targets (enzymes, 
receptors, ion channels etc) need to be identified (Gashaw et al., 2012). In order to 
meet the challenges of new therapy discovery, recent work has focused on the lipid 
species and biosynthetic enzymes found in T. gondii, and other apicomplexan 
parasites, but not in their mammalian hosts (Denny et al., 2006; Mina et al., 2009). 
These pathways are now regarded as appropriate drug targets in efforts to find 
alternative T. gondii treatments with less side effects than current therapies (Sonda 











Lipids are important structural components of cell membranes regulating the 
permeability between the extracellular and intracellular compartments (Ohanian 
and Ohanian, 2001; Pralhada Rao et al., 2013). There are two major classes of lipids, 
glycerolipids and sphingolipids (SLs), and both play an important role in numerous 
cell processes, including signal transduction (Ohanian and Ohanian, 2001; Pratt et 
al.,2013). 
SLs were first discovered by Thudichum in 1876, and are regarded as an essential 
class of lipids that are ubiquitous constituents of eukaryotic membranes (Bartke and 
Hannun, 2009). SLs play a major role in regulating many important processes, such 
as apoptosis, angiogenesis, genetic diseases and chemotherapy resistance 
(Ogretmen and Hannun, 2004; Merill, 2002; Heung, 2006; Pratt et al., 2013). The 
basic structural characteristic of SLs is a sphingoid backbone, which can be 
distinguished amongst mammalian and yeast and plant cells. In mammals 
sphingosine is the most common sphingoid base, whilst phytosphingosine is more 
common in yeast and plants (Ohanian and Ohanian, 2001). There are many enzymes 
and metabolites involved in mammalian SL biosynthesis, changes in enzyme activity 
and metabolite levels as result of alterations in gene expression can lead to severe 
diseases such as Alzheimer’s disease (Haldar et al., 2002).   
The initial steps of  de novo SL synthesis lead to the formation of ceramide (Michael 
and Echten-Deckert, 1997; Bartke and Hannun, 2009).This occurs on the cytosolic 
surface of the ER (Bartke and Hannun, 2009 ; Romano et al., 2013) and begins with 
the condensation of serine and palmitoyl coenzyme A to form 3-keto-
dihydrosphingosine (KDS), a reaction catalyzed by the enzyme serine 
palmitoyltransferase (SPT) (Denny  et al., 2006 ; Bartke and Hannun, 2009 ; Beattie 
et al., 2013 ; Genin et al., 2016). Three kinds of SPT-related genes have been 
identified in eukaryotes, SPTLC1 (LCB1), SPTLC2 (LCB2) and SPTLC3 (Hanada et al., 
2003; Ikushiro and Hayashi, 2011; Genin et al., 2016) (figure 1-5). The active site of 
SPT is centered on a lysine (Merrill, 2002). The core eukaryotic SPT is a heterodimer, 
containing LCB1 and LCB2 (Buede et al., 1991, Nagiec et al., 1994). In mammals, an 
additional subunit SPTLC3 has been identified (Hornemann et al., 2006). Mutation in 




human LCB1 and LCB2 (Han et al., 2009) leads to hereditary sensory and autonomic 
neuropathy type I (HSAN1) (Beattie et al., 2013). 
KDS is subsequently reduced to dihydrosphingosine, then acylated and desaturated 
to form ceramide in mammals whereas, in yeast and plants, dihydrosphingosine is 
hydroxylated to form phytosphingosine before acylation to create phytoceramide 
(Heung et al., 2006). In mammalian systems, the ceramide formed is incorporated 
into complex SLs such as sphingomyelin (SM) and glycosphingolipids (GSLs) in the 
Golgi apparatus, whilst in fungal and plant cells phytoceramide is used to form 
inositol-containing complex SLs, inositolphosphoryl ceramide (IPC) and its 
mannosylated derivatives. Many fungi also use phytoceramide to produce 
glucosylceramide (Figure 1-5).  
Sphingosine and ceramide perform key roles in this pathway, for instance as 
substrates to produce sphingosine-1-phosphate (S-1-P) and ceramide-1-phosphate 
(C1P). Ceramide and sphingosine works as tumor-suppressor lipids by modulating 
cellular processes like apoptosis, growth arrest and differentiation. Meanwhile C1P 
and S1P acts as tumor-promoting lipids participated in cell proliferation, migration, 
inflammation and blood vessel development (Hanada, 2005, Pralhada Rao et al., 
2013). High levels of pro-growth SLs like S1P lead to an increase in the proliferation 
of cancer cells which results in the avoidance of therapy-induced apoptosis 
(Gottesman, 2002). Low levels of cellular ceramide induce the same effect (Pralhada 
Rao et al., 2013).  
Two metabolic pathways result in ceramide formation, the first one is the de novo 
anabolic route oulined above which consists of a series of enzymatic reactions which 
produce ceramide from the simple components (Delgado et al., 2006). The second is 
a catabolic pathway, the hydrolysis of complex SLs particularly SM and 
glycosphingolipids (GSLs) (Delgado et al., 2006). Ceramide accumulation induces 
cellular apoptosis and is associated with many diseases such as Type II Diabetes 
Mellitus (T2DM) (Chavez et al., 2003), Alzheimer’s disease (Beattie et al., 2013, 
Lindholm et al., 2006) and hepatocellular carcinoma (Pralhada Rao et al., 2013).  
SL biosynthesis appears to be largely conserved in the parasitic protozoa. However, 
whilst some parasites such as P. falciparum produce SM like mammalian cells others, 




for example the kinetoplastid Leishmania species, produce fungal/plant-like IPC 
(Mina et al., 2009), the following key SLs are produced from this pathway: 
1. SM is an abundant ingredient of animal plasma membranes where it forms 5-
15% of total lipids (Tafesse et al., 2007). SM production is catalyzed by SM 
synthase (SMS). There are two orthologues of this enzyme in mammals SMS1 
and SMS2: SMS1 located at the Golgi apparatus and SMS2 at the plasma 
membrane (Huitema et al., 2004, Tafesse et al., 2007). SM is found in a high 
concentration in the outer leaflet of the plasma membrane where, by its affinity 
to sterols, it helps establish a solid barrier to the extracellular environment and 
forms specialized microdomains in the plasma membrane (PM) called lipid rafts 
(Denny et al., 2006). These rafts play essential roles in signal transduction and 
the polarized trafficking of lipid modified proteins (Simons, and Ikonen, 1997; 
Pratt et al., 2013). These sterol and sphingolipid rich lipid rafts are found in 
parasites such as Entamoeba histolytica, Giradia lamblia, Leishmania spp., 
Trypanosoma spp. and T. gondii. The lipid rafts play fundamental roles in 
invasion by regulating the adhesion to host, perturbing host cell rafts leading to 
the dysregulation of membrane function and easing the establishment of 
infection, and eluding the host immune response (Goldston et al., 2012). In order 
to show the roles of lipid rafts in adhesion, Giardia lamblia and Entamoeba 
histolytica were treated with a cyclic compound chelating cholesterol, methl-β-
cyclodextrin (MβCD), were unable to adhere to the host cells (Humen et al., 
2011, Welter et al., 2011). Moreover, Goldston et al., 2012 showed that T. cruzi 
treated with MβCD were inhibited in invasion, suggesting a role for lipid rafts in 
this process. Additionally, lipid rafts work as a reservoir for lipid signaling 
molecules including ceramide, sphingosine and S-1-P which are responsible for 
many pivotal intracellular processes such as apoptosis, cell proliferation and 
differentiation (Ogretmen and Hannun, 2004, Spiegel and Milstien, 2003).  
2. IPC synthesis is catalyzed by inositol phosphorylceramide synthase (IPCS) 
through the transfer of a phosphorylinositol head group from 
phosphatidylinositol to ceramide (Denny et al., 2006) (figure 1-5). IPCS (and IPC) 
is absent in mammalian cells and so it is regarded as one of the most attractive 
drug targets for certain fungal and protozoan pathogens. Indeed, modulation of 




the production of SLs is regarded as one of the primary new strategies in 
therapeutic treatment of infectious and non-infectious diseases (Wedsworth, 
2013), thus most of the future studies in this field will be focused on the enzymes 
that play important roles in sphingolipid biosynthesis, such as SPT and IPCS 
(Denny et al., 2006; Mina et al., 2009). There are small numbers of specific 
inhibitors for SPT all of which are natural products, for example lipoxamycin, 
viridiofungin A, sphingofungins and myriocin (Wedsworth, 2013). Similarly there 
are a few specific, natural compound, inhibitors of the fungal IPCS, such as cyclic 
depsipeptide aureobasidin A (AbA) which was isolated from the fungus 
Aureobasidium pullulans R106  (Ikai et al. 1991 ; Takesako et al. 1993). 
All eukaryotic cells thus far studied (animal, plant, protozoa and fungi) synthesize SLs 
de novo. In addition, even though non-eukaryotes do not generally synthesize these 
lipids, many bacterial and viral pathogens depend on the host SLs to promote 
virulence (Casadevall and Pirofski, 2003; Heung et al., 2006). Some studies have 
reported that the eukaryotic parasites, such as T. gondii, also salvage lipids from the 
host, including cholesterol and phospholipids (Coppens et al., 2000; Charron et al., 
2002). However, T. gondii also depends on de novo lipid synthesis, for instance of 
phosphatidyl choline (PC) particularly when host PC is limited (Charron et al., 2002). 
This study demonstrated that host PC is not essential for parasite growth and survival 
and indicated the importance de novo synthesis in parasitism (Pratt et al., 2013 ; 
Alqaisi et al., 2017). 
The recent studies have focused on the SL biosynthetic pathway because the final 
products, and the synthetic enzymes, are different in mammals, fungi, plants and 













Figure (1-5) Sphingolipid biosynthesis pathways of mammalian and fungal cells 
(adopted and modified from Hanada, 2004). 
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1.9 Sphingolipids in Toxoplasma gondii 
The negative impact of protozoan pathogens on human health and prosperity is 
enormous, for example malaria which is caused by the apicomplexan Plasmodium 
spp., is responsible for approximately 214 million cases and more than 439.000 
deaths each year. Trypanosomatid parasites, which include Trypanosoma cruzi, 
Trypanosoma brucei and Leishmania spp, infect 20-30 million people worldwide, 
causing various diseases ranging from disfiguring skin lesions to lethal systemic 
disease. Other protozoan parasites like Giardia spp. and Entameoba histolytica can 
also cause severe human disease (Zhang et al., 2009). There are currently no vaccines 
available for any of these diseases and there is a lack of effective drugs for many of 
them. Many of the available therapies are characterized by low efficacy, high toxicity 
and wide spread resistance (Simmaro et al., 2004; Croft and Coombs, 2003). 
Therefore, recent work has focused on identifying parasite-specific essential 
pathways and developing the novel inhibitors that target them (Zhang et al., 2009). 
The structure and function of sphingolipids in parasitic protozoa differ when 
compared with mammals, fungi and plants. Some protozoa, such as the 
trypanosomatid Leishmania spp., synthesize large amounts of unglycosylated IPC, 
whereas the related parasite Trypanosoma brucei synthesizes SM in addition to IPC 
(Zhang et al., 2009). The apicomplexan parasite Plasmodium spp. synthesizes SM and 
GSL like their mammalian host, whilst its relative T. gondii also synthesizes non-
mammalian IPC. IPC, and the biosynthetic enzyme IPCS, are essential for fungi 
(Mandala et al., 1998), plants and trypanosomatid species (Sonda et al., 2005; Pratt 
et al., 2013). T. gondii also contains other SL, including high levels of ethanolamine 
phosphorylceramide (EPC) but lower levels of SM compared with the mammalian cell 
host (Welti et al., 2007). In fact, T. gondii have more than 20 species of SL consisting 
of either saturated or unsaturated fatty acids (Lige et al., 2011). Despite the ability of 
T. gondii to support de novo synthesis the parasite also scavenges SLs from the host 
cell via the host Golgi or the endocytic system (Bisanz et al., 2006; Pratt et al., 2013; 
Romano et al., 2013). 
The many sources of SL for T. gondii are listed below:  




1. When added exogenously, ceramide is directed towards the host cell Golgi 
apparatus, where it can be incorporated into SM or GSL and salvaged by the 
infecting T. gondii (Pratt et al., 2013; Romano et al., 2013) (Figure 1-6 A). 
2. In the host cell ceramide produced by de novo synthesis in the endoplasmic 
reticulum is transported to Golgi apparatus and converted to SM or GSL 
which then can be salvaged by T. gondii through intercepting Golgi-derived 
vesicles (Rab14, Rab30 and Rab34) (Romano et al., 2013). When T. gondii 
invades a mammalian it forms its own-membraneous compartment, the PV. 
Notably the PV is located near the host Golgi and here the parasite can hijack 
Golgi-derived vesicles and scavenge SL (Romano et al., 2013). These vesicles 
and soluble transporters in the cytosol, such as ceramide transfer protein 
(CERT) play important roles in the trafficking of SL (Bartke and Hannun, 2009) 
(figure 1-6 B). 
3.  Neutral sphingomyelinase (nSMase), which is in the host plasma membrane 
(figure 1-6 C) catalyses the hydrolysis of SM, converting it to ceramide which 
can be scavenged by T. gondii.  
4.  Acid sphoingomyelinase (aSMase) performs a similar role to the neutral 
sphingomyelinase but is located in the endolysosome (figure 1-6 D).  
5. T. gondii de novo synthesis, like all eukaryotes, begins with condensation of 
serine and palmitoyl CoA, catalyzed by serine palmitoyl transferase (SPT), to 
form 3-ketodihydroshingosine (KDS) which is then converted to ceramide 
which is subsequently converted to either SM or IPC (Azzouz et al., 2002; 














Figure (1-6) showing the sources for sphingolipid for Toxoplasma gondii (modified 
from Romano et al., 2013). PM: plasma membrane; SM: sphingomyeline; SPT: 
serine palmitoyl transferase; CerS: ceramide synthase; Des: desaturate; ER: 
endoplasmic reticulum; nSMase: neutral sphingomyelinase; aSMase: acid 
sphingomelinase; CER: ceramide transport proteins; PV: parasitophorous vacuole; 
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Kinetoplastids are flagellated parasites characterised by having a structure called 
kinetoplast which contains DNA, this group includes Trypanosoma brucei which 
causes African sleeping sickness, Trypanosoma cruzi the causative agent of Chagas 
disease, and Leishmania spp. which cause leishmaniasis (Burri and Brun, 2003). All 
the members have a singular flagellum that originates from a basal body near the 
kinetoplast (region containing the mitochondrial genome) and extends to the outside 
of the cell (Landfear and Sanchez, 2015). Approximately 500 million persons in 
tropical and sub-tropical areas are at risk of infection with these parasites, 20 million 
are estimated to be infected and at least 100.000 deaths result each year (Stuart et 
al., 2008; Pana et al., 2015).  In this study, Leishmania major was used as a model to 
show the global role of SL biosynthesis pathway in the parasite by exploiting the in-
house availability of IPCS inhibitors.    
  
1.11 Leishmaniasis 
Leishmaniasis is a widespread disease caused by Leishmania spp. and transmitted by 
the sandfly vector. It is estimated that more than 150 million individuals in 98 
countries are infected (Alvar et al., 2012; Hurrell et al., 2016), and that 350 million 
life at risk of infection (Leifso et al., 2007; Bolt et al., 2016; Hurrell et al., 2016). 
Leishmaniasis has the highest burden of morbidity of all protozoan infections after 
malaria (Field et al., 2010; Savoia, 2015). This disease is endemic in regions such as 
Latin America, South East Asia, East Africa and the Mediterranean (Pace, 2014). 
Distribution is exacerbated in countries suffering from conflict and poor health 
systems (Beyrer et al., 2007; Kerridge et al., 2012). In addition, it has been 
demonstrated that Leishmania/HIV co-infection in problem in the Mediterranean 
region and beyond (Monge-Maillo et al., 2014).  
Against this backdrop, the World Health Organisiation (WHO) is focusing on 
leishmaniasis and on the development of the new tools to find effective drugs or 
vaccines (Desjeux, 2004).  
Leishmaniasis is categorized depending on its geographical distribution into two 
types: 




1. Old World leishmaniasis, including the areas of Southern Europe, 
Mediterranean, Middle East, Asia and Africa (Ready, 2000; McGwire and 
Satoskar, 2013). In this type, the parasite is transmitted to human by sandflies of 
the genus Phlebotomus (Mansueto et al., 2014; Vermelho et al., 2017). 
2. New World leishmaniasis including Latin American (Ready, 2000; McGwire and 
Satoskar, 2013). In this type, the parasite is transmitted to human by sandflies of 
the genus Lutzomiya (Mansueto et al., 2014; Vermelho et al., 2017).      
Leishmania have more than 53 species (Cotton, 2017), 20 of them are infective to 
humans (Naula et al., 2005; Mansueto et al., 2014; Cotton, 2017). Leishmania spp. 
cause four main diseases depending on the localization of infected macroophages in 
mammalian tissue, these diseases are: cutaneous (CL), visceral (VL), mucocutaneous 
(MCL) (Naula et al., 2005) and diffuse cutaneous leishmaniasis (DCL) (Akhoundi et al., 
2016). An estimated two million new cases of leishmaniasis occur per year; 500.000 
VL and 1.500.000 CL (Mansueto et al., 2014; Hurrell et al., 2016). The manifestation 
of these diseases ranges from superficial infection to fatal visceral disease of humans 
and other animals such as the dogs (Handman and Bullen, 2002), which are a 
domestic reservoir host for Leishmania spp. and play an essential role in the 
transmission cycle between humans and sandflies (Gramiccia and Gradoni, 2005; 
Chávez-Fumagalli et al., 2015).  
Leishmania spp. can avoid the host immune system using many strategies such as 
manipulating numerous pathways related to cell signaling and phagocytosis, and 
modifying the production of cytokines and chemokines in the infected macrophage 
(Mougneau et al., 2011; Gupta et al., 2013). Leishmania spp. can also terminate the 
apoptotic process of the  macrophage. These strategies help the parasite to avoid the 
immune system and proliferate (Guttierrez-Kobeh et al., 2013). 
The most important species that cause CL and MCL are: L. tropica which causes CL or 
dry oriental sore (Hotez, 2008; Handman and Bullen, 2002) and is widely distributed 
in Asia, Africa and the Middle East (Joshi et al.,2008) - particularly Iraq, Iran, 
Afghanistan, Syria, Morocco, Palestine, Saudi Arabia and Yemen (Postigo, 2010); L. 
major, which has a rodent reservoir (Rhombomys, Psammomys and Arvicanthis; 
Handman and Bullen, 2002) and causes a CL or rural, wet oriental sore (Handman 
and Bullen, 2002 ; Hotez, 2008), it is widely distributed in Iraq, Iran, Afghanistan, 




Egypt, Libya, Jordan, Morocco, Palestine, Saudi Arabia, Tunisia, Yemen and Pakistan 
(Postigo, 2010); L. braziliensis, also infects sloths and dogs  (Handman and Bullen, 
2002), causes CL or MCL in Latin America, particularly Brazil (Carneiro et al., 2016); L. 
aethiopica, also infects the Rock Hyrax, causes CL or DCL primarily in East Africa 
(Handman and Bullen, 2002). L. mexicana which also infects forest rodents, causes 
CL or DCL (Hotez, 2010), and is found in US, particularly along the border with Mexico 
(Hotez, 2008).  
CL is mostly found in 10 countries: Columbia, Peru, Brazil, Costa Rica, Iran, Syria, 
Ethiopia, Algeria, Afghanistan and North Sudan (Alvar et al., 2012; Akhoundi et al., 
2016). The disease is characterized by a localized lesion at the site of insect bite 
(Hurrell et al., 2016; Cotton, 2017), particularly on the exposed areas of the body 
such as the face, forearms and lower legs (Naula et al., 2005; McGwire and Satoskar, 
2013). The manifestation starts with a tiny erythema developing into a papule then 
a nodule, after 2 weeks to 6 months a lesion develops (Reinthinger et al., 2007) with 
a diameter ranging between few millimeters to several centimeters (Ashford, 2000). 
MCL is primarily caused by L. braziliensis, the symptoms can appear after many years 
following the initial bite and are characterised by metastatic lesions manifest on the 
nasal or buccal mucosa, these then develop to destroy parts of face because of the 
erosion of cartilage (Ashford, 2000; Naula et al., 2005; McGwire and Satoskar, 2013). 
The distribution of DCL is limited to Latin America (Venezuela and Republic of 
Dominican) and East Africa (Ethiopia and Kenya). The lesions in this case spread all 
over the body (Ashford, 2000).      
The most important Leishmania spp. that cause VL are L. donovani, particularly in the 
Old World, and L. infantum in the Mediterranean region and Brazil, where is known 
by its synonym L. infantum chagasi (McGwire and Satoskar, 2013; Messaoud et al., 
2017). VL is seen in humans, dogs and savannah rodents (Handman and Bullen, 2002) 
and is known as kala azar in India, with post kala azar dermal leishmaniasis (PKDL) a 
major complication. VL is widely distributed but more than 90% of all cases occur in 
six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia (Alvar et al., 
2012; Akhoundi et al., 2016). McGregor, 1998 reported that more than 10% of the 
population died in an outbreak in Southern Sudan because of this infection. VL is 
characterized by an ulcerated lesion at the site of insect bite (Ashford, 2000) from 




where the parasites spread from the skin to other organs, particularly the spleen and 
liver (Cotton, 2017). This is accompanied by systemic signs appearing after weeks, 
sometimes years, such as splenomegaly, hepatomegaly and anemia which ultimately 
lead to the organ failure (Desjeux, 2001; Rice et al., 2016) and death if left untreated 
(Ashford, 2000 ; Desjeux, 2004 ; Hurrell et al., 2016). In some cases VL symptoms are 
like those of autoimmune disease which can lead to misdiagnosis and inappropriate 
treatment, therefore caution is required in diagnosis (Xynos et al., 2009; Sotirakou 
and Wozniak, 2011).  
PKDL is characterised by skin mottling two years after the complete cure of VL 
(Ashford, 2000).  
Furthermore, Leishmania spp. are also classified according to the location of  
development in sandfly gut: Leishmania leishmania and Leishmania viannia (Foulet 
et al., 2007; Pace, 2014).   
1.11.1 Life cycle 
Leishmania spp. are heteroxenous parasites which means they require two hosts to 
complete the life cycle (Dantas-Torres et al., 2010; Solano-Gallego et al., 2012; 
Akhoundi et al., 2016): a vertebrate host (including humans) and an invertebrate 
vector, the sandfly (Handman and Bullen, 2002). Leishmania spp. has two life cycle 
stages, the intracellular amastigote stage in vertebrate host macrophages, and the 
extracellular promastigote stage in sandfly vector (Leifso et al., 2007; Singh and 
Singh, 2012; Hurrell et al., 2016). Life cycle starts when the vertebrate hosts are 
infected by Leishmania spp. via the bite of infected female sandfly (Akhoundi et al., 
2016). Inside the vertebrate host, the inoculated metacyclic promastigotes (the 
infective stage) are phagocytosed by macrophages which form a phagosome, this 
fuses with lysosome to form a phagolysosome where the promastigote differentiates 
into the amastigote (the pathogenic stage) (Handman and Bullen, 2002; Sereno et 
al., 2007) (figure 1-7). In CL the infected macrophages are derived from inflammatory 
monocytes, whilst in VL the parasites infect Kupffer cells, the macrophage cells in 
both the spleen and bone marrow (Kaye and Scott, 2011; Ribeiro-Gomes et al., 2012). 
The CL symptoms takes 2 weeks to 3 months to be shown (Goto and Lindoso, 2010), 
whilst it takes 1-12 months in ML (Fletcher et al., 2015). The amastigote is 
characterised by its round shape (diameter 5 µm) and the ability to survive and 




multiply within phagolysosomes (Ashford, 2000; Cotton, 2017). Amastigotes have 
kinetoplasts like promastigotes, but only immature flagella, they multiply by 
longitudinal binary fission until the host cell bursts and the parasites infect another 
cell (Ashford, 2000). Subsequently, a sandfly can ingest this stage via a blood meal 
when they feed on the blood from infected person, then inside the insect gut it 
transforms into the promastigote stage which is characterised by an elongated body 
and a well developed flagellum emanating from the kinetoplast (Ashford, 2000). This 
stage needs 8-20 days to transform to infective metacyclic promastigotes (Gossage 
et al., 2003; Desjeux, 2004). In some cases, Leishmania spp. can be transmitted from 
human to human without the insect vector, such as by organ transplantation, sexual 
contact and blood transfusion (Ansari et al 2013; Monge-Maillo and López-Vélez, 
2013). Leishmaniasis can also spread from an endemic to non-endemic area by many 
ways, such as urbanization, natural catastrophe, tourism and armed combat 
(Reithinger et al., 2007; Soreno et al., 2007). 
Figure (1-7) Depiction of the Leishmania spp. life cycle (adopted and modified from 
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Depending on its location and the infecting species, leishmaniais is diagnosed by one 
of these methods: 
1. In CL a skin biopsy to examined microscopically for amastigotes (Reed, 1996; 
Desjeux, 2004; Stuart et al., 2008). 
2. In VL amastigotes are looked for microscopically in a blood smear or aspirates 
from bone marrow or spleen (Ashford, 2000). 
3. In VL serological tests are also used such as Enzyme Linked Immunosorbent 
Assay (ELISA), the ImmunoFluorescence Antibody Test (IFAT) and direct 
agglutination (Desjeux, 2004). 
 
1.11.3 Treatment 
A limited range of drugs is available for use against Leishmania spp. infections (Bolt 
et al., 2016). The historic, first line drugs are the pentavalent antimonials (Sbv), 
Pentostam (sodium stibogluconate) and Glucantime (meglumine antimoniate) (Tuon 
et al., 2008; Kedzierski et al., 2009; Chadbourne et al., 2011; Chávez-Fumagalli et al., 
2015). These drugs have an unclear mode of action, exhibit many side effects 
exemplified by renal failure and cardiotoxicity (Chappuise et al., 2007; McGwire and 
Satoskar, 2013; Chávez-Fumagalli et al., 2015), and require parenteral administration 
(Demicheli et al., 2004). In addition, because they have been in use for more than 70 
years, ago, the parasite is showing resistance against pentavalent antimonials (Croft 
and Coombs, 2003; Chappuise et al., 2007; Bolt et al., 2016).  
Paromomycin is an aminoglycoside antibiotic that is active against both bacteria and 
Leishmania spp. (Singh and Singh, 2012). Its mechanism of action against bacteria is 
the inhibition of protein synthesis by binding to 16s rRNA, it is unclear in Leishmania 
spp. Paromomycin has many side effects such as nephrotoxicity and effects on the 
vestibular system, particularly related to the inner ear leading to vestibular 
instability. This drug also requires parenteral administration (Ben Salah et al., 2013).  
Amphotericin B (Fungizone) is very active against Leishmania spp. and has become a 
first line drug in a liposomal formulation (AmBisome) (Meyerhoff, 1999; Goldstone 
et al., 2012; McGwire and Satoskar, 2013; Chávez-Fumagalli et al., 2015). 




Amphotericin B was first established as an anti-fungal (Marcondes et al., 2011). Fungi 
contain ergosterol as their primary sterol and the mechanism of action of 
amphotericin B is binding to this sterol that is also a plasma membrane component 
in Leishmania spp. (Barratt and Legrand, 2005 ; Chávez-Fumagalli et al., 2015 ; 
Vermelho et al., 2017). This leads to cell death because of increased cell permeability 
and the leaking of intracellular contents (Seifert, 2011; Castillo et al., 2010; Goldstone 
et al., 2012; Vermelho et al., 2017). AmBisome is used for VL treatment in the 
endemic areas such as Bihar, India where resistance to antimonials compounds is a 
problem (Saravoltaz et al., 2006). However, its high cost is a limiting factor (Sundar 
et al., 2001; Desjeux, 2004; Chávez-Fumagalli et al., 2015). Amphotericin B requires 
parenteral administration and exhibits side-effects such as nephrotoxicity, liver 
damage, hemolysis and cardiac alterations, although these are reduced in the 
liposomal formulation AmBisome (Annaloro et al., 2009; Singh and Singh, 2012). 
Pentamidine is a second line drug (Singh and Singh, 2012), and its mode of action has 
been proposed as binding with macromolecules such as DNA, RNA, lipids and 
proteins. Pentamidine has many side effects including cardiotoxicity such as heart 
failure, hypotension, in addition to hypoglycemia, leukopenia, anemia and 
nephrotoxicity. In addition, it requires parenteral administration (Hellier et al., 2000).  
Miltefosine was developed as an anti-cancer drug (Dorlo et al., 2012; Rice et al., 
2016) and is the first oral drug for leishmaniasis. It is now used for CL and VL (Croft 
and Coombs, 2003; Soto et al., 2009; Bolt et al., 2016), particularly from 2002 in India 
(George et al., 2006). Its mode of action has been proposed to be the manipulation 
of Leishmania spp. intracellular Ca+2 homeostasis (Serrano-Martin, 2009; Benaim et 
al., 2013). Ca+2 plays important roles in parasite invasion and differentiation (Moreno 
and Docampo, 2003; Benaim et al., 2013), so disruption of Ca+2 homeostasis can be 
anti-parasitic. Its adverse effects are nausea and vomiting, and because it is 
teratogenic it is not recommended for the treatment of pregnant women (Naula et 
al., 2005; Sundar et al., 2006; Dorlo et al., 2012; Singh and Singh, 2012). 
In addition to the drugs above, other types of treatment are used for leishmaniasis 
such as: cryotherapy used to treat CL caused by L. tropica, L. aethiopica and L. 
infantum, with liquid nitrogen once to up to five times for 3-7 days (Negera et al., 
2012); and heat therapy which is recommended for HIV patients with CL who do not 




respond to the classical treatments, the lesion is heated to 50  ̊C for 30 seconds up to 
3 times per day (Reithinger et al., 2005; Bumb et al., 2013). 
 
1.11.4 Anti-leishmanial drug targets 
No active vaccines are available against Leishmania spp. (Chadbourne et al., 2011; 
Bolt et al., 2016) in addition, as described above, drug treatments are limited with 
many problems. Therefore, there is now a need to design effective drugs with less 
adverse side-effects (Vyas and Gupta, 2006). However, the development of new 
drugs takes between 10 and 20 years and costs up to $1 billion (Bleicher et al., 2003; 
Hughes et al., 2011). Therefore new, well validated drug targets are essential. The 
properties of such targets are: i. It is fundamental for parasite growth and survival; ii. 
It is preferably unique to the parasite; iii. If both host and the parasite have the same 
pathway, a drug should be selective (Fairlamb, 2003; Frearson et al., 2007). Also it is 
important to develop more than one drug for each pathogen to obviate the 
resistance when it emerges (Stuart et al., 2008).  
Thus, the recent studies have focused on the fundamental metabolic pathways in 
Leishmania spp., and particularly on the enzymes that catalyze reactions in these 
pathways that may be new drug targets (Denny et al., 2006; Singh and Singh, 2012; 
Pratt et al., 2013; Vermelho et al., 2017). 
 
1.11.5 Leishmania spp. sphingolipid biosynthetic pathway 
The primary complex SL in Leishmania spp is IPC, which is estimated as comprising 5-
10% of total membrane lipids (Zhang et al., 2005). As discussed above, IPC synthase 
(IPCS) is a non-mammalian enzyme that catalyzes the transfer of phosphorylinositol 
from phosphatidylinositol to the 1-OH group of ceramides or phytoceramide to form 
IPC (Lester and Dickson, 1992; Hsu et al., 2007; Mandlik et al., 2012). IPCS is an 
essential enzyme in Saccharomyces cerevisiae, where it is known as AUR1p (Nagiec 
et al., 1997; Hsu et al., 2007) and is an attractive target for anti-fungal drugs such as 
aureobasidin A (Nagiec et al., 1997; Zhong et al., 2000; Wuts et al., 2015). Zhang et 
al., (2003) showed that both Leishmania spp. stages (amastigote and promastigote) 




have a high IPC levels and IPCS is an attractive drug target in this protozoan parasite 
(Denny et al. (2006).  
 
1.12 Aim of the study 
It has been shown that the salvage of SLs from the host is non-essential for 
Toxoplasma gondii proliferation and pathogenesis, indicating the importance of de 
novo SL synthesis in this protozoan pathogen (Pratt et al., 2013). It is well known that 
the enzymes that mediate protozoan SL biosynthesis represent key drug targets 
(Denny et al., 2006; Young et al., 2012) and the currently poorly characterized 
pathway in Toxoplasma has also been proposed as a target for chemotherapeutic 
intervention (Sonda et al., 2005; Pratt et al., 2013). Using bioinformatics and 
biochemical approaches the pivotal, but divergent, enzymes in Toxoplasma 
biosynthesis have been identified in the Denny laboratory. This project aims to 
functionally characterize key identified enzymes in the biosynthetic pathway and 
investigate the possibility of targeting the pathways therapeutically. In addition, 
using Leishmania major and the availability of in house identified inhibitors, the 
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The materials used in this study were described in table (2.1): 
Table 2.1 The materials and their source: 
Materials Source 
96 well assay plate, black plate Costar 
96 well assay plate, cell culture cluster, flat 
bottom with low evaporation lid 
Costar 
Acid glass beads SIGMA 
Agar Granulated broth Melford 
Alamar blue Invitrogen 
Aureobasidin A and analogue Cmpd20 AureoGen 
Chloroform Fisher 
Chloroform Chromasolv SIGMA 
DAPI Fluoromount Southern Biotech 
Dream Taq DNA Polymerase Thermo Scientific 
Dulbecco's Modified Eagle Medium 
 DMEM  
Gibco® by Life Technologies  
EDTA SIGMA 
Efficiency® DH5α competent cells  Invitrogen 
Ethanol Fisher 
F-12+Glutamax™ nutrient Mixture (Ham) Gibco® by Life Technologies 
Fetal calf serum  Labtech 
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FluoroBrite™ DMEM Media Gibco® by Life Technologies 
ImPromII Reverse Transcriptase System Promega 
In-Fusion® HD Cloning Kit Takara 
KCl BDH 
LB broth granulated MELFORD 
L-Serine SIGMA 
L-Glutamine  SIGMA 
Membrane filters 5 µM and 3 µM Millipore 
Methanol Fisher 
Methanol LC-MS ultra chromasolv UPLC-MS FLUKA 
Midiprep kit QIAGEN 
Miniprep kit QIAGEN 
NaCl MELFORD 
NBD-C6-Ceramide complexed to Bovine 
Serum Albumin (BSA) 
Life Technologies 
PBS tablets Invitrogen 
PBS tablets Gibco 
Penicillin/Streptomycin-Glutamine solution Hyclone 
Platinum® Taq DNA Polymerase High 
Fidelity  
Life Technologies 
Palmitoyl Co-A SIGMA 
Power broth Molecular Dimension 
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Restriction enzymes: NotI, XhoI, HindIII, 
SacII, PacI and EcorI 
Thermo Scientific 
RNeasy Mini Kit QIAGEN 
Schneider’s Insect Medium SIGMA 
Schneider’s medium SIGMA 
SDS SIGMA 
SYBR®Green Jump Start™ SIGMA-ALDRICH 
T4 DNA Polymerase LIC qualified  Novagen 
Terreffic broth SIGMA 
Tris SIGMA 
Trypsin-EDTA 10X 5% Gibco® by Life Technologies 
 
Vero cells, RHΔHX Toxoplasma gondii and the plasmid TgCATtsag1KO were supplied 
by Dominique Soldati, University of Geneva. Δku80-HXG T. gondii (Huynh and 
Carruthers, 2009) were supplied by Vern Curruthers, University of Michigan. RH-HX-
KO-YFP2-DHFR T. gondii were supplied by Boris Streipen, University of Georgia. The 
plasmids pG27 LIC-YFP-DHFR and pG1 mycGFPPfmyoAtailTy were supplied by 
Markus Meissner, University of Glasgow. P30 GFP_HDEL (Pfluger et al., 2005) and 
P30 GRASP_RFP (Catherine and Linstedt, 2016) were supplied by Kristin Hager, 
University of Notre Dame. Mouse anti-TY monoclonal antibody was supplied by Keith 
Gull, University of Oxford. Human Foreskin Fibroblast (HFF) cells were supplied by 
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2.2 Transformation protocol 
2.2.1 Preparation of Luria broth (LB) broth and LB agar 
2.2.1.1 LB broth 
This broth was prepared by adding 25 g of LB broth in 1L distilled water  
2.2.1.2 LB Agar 
This agar was prepared by adding 25g of LB broth, 15 g of agar-agar in 1L distilled 
water. 
2.2.2 Transformation to the competent cells 
Aliquots of the chemically competent cells E. coli DH5α were thawed on ice, once 
thawed 50 µl of the cells were transferred to an Eppendorf tube, then 1-5 µl of the 
diluted plasmid DNA (100 pg – 100 ng) were added, and mixed well by swirling the 
tube, then incubated on ice for 30 minutes (mins). Heat shock was performed in a 
water bath at 42°C for 30 seconds (sec), then cells are put on ice again for 2 mins. 
250 µl of LB broth or pre-warmed S.O.C. media without antibiotics was added to the 
cells, then incubated for 1 hr in a shaking incubator at 37 °C. 
About 100-200 µl of cells were plated on the LB agar with antibiotic (Ampicillin 100 
mg/ml), and left for several minutes to dry, then incubated at 37 °C for 16-20 hours. 
  
2.2.3 Isolation of Plasmid  
A single colony from an LB agar plate was taken, and inoculated into a 5 mL LB broth 
with appropriate antibiotics (Ampicillin 100 mg/ml), and mixed together in a shaker 
incubator at 37°C overnight.  The plasmid DNA was prepared using a miniprep kit 
(QIAGEN) according to manufacturer’s protocol. The plasmid DNA concentration was 
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2.3 Gel Electrophoresis 
Agarose gel 0.8% (V/V) was prepared by dissolved 8.0g of agarose in 1000 ml 1X 
TAE buffer (SIGMA). DNA samples were mixed with 6X DNA loading dye (1:5, 
QIAGEN), then loaded on the agarose gel then, using BioRad 3000 power pack, 
run at 100 volts for 45 mins.  
 
2.4 Cell culture 
Dulbecco's Modified Eagle Medium (DMEM) was used for cell culture, and was 
prepared by adding heat-inactivated Fetal Calf Serum 10% and 
penicillin/streptomycin 1%. Vero and HFF cells, and RHΔHX, RH-HX-KO-YFP2-
DHFR and Δku80-HXG T. gondii were maintained in DMEM media at 37°C and 5% 
CO2 CHO cells were maintained in F-12+Glutamax™ nutrient mixture (Ham), 10% 
Fetal Calf Serum and 1% penicillin/streptomycin, at 37°C and 5% CO2.  
 
2.5 RNA Extraction from CHO cells 
Two T25 flasks of CHO cells maintained in DMEM media were prepared and one 
infected with 5x106 parasites. After 72 hours CHO cells were detached from the 
T25 flasks by adding Trypsin/EDTA and the RNA extracted using the RNeasy kit 
according to the QIAGEN protocol. The concentration of RNA was measured by a 
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2.6 Preparation cDNA from RNA 
The ImPromII Reverse Transcriptase System protocol provided by Promega was 
followed to synthesize cDNA from RNA samples: 
1. The experimental RNA was thawed on ice. 
2. The reaction sample was made for each of infected and uninfected CHO cells 
in cooling condition as follows: 
 Infected CHO Samples Uninfected CHO Samples 
 Experimental Negative Experimental Negative 
RNA (up to 1 
µg) 
X µl - X µl - 
Random 
primers 
1 µl 1 µl 1 µl 1 µl 
Nuclease-free 
water 
X µl 4 µl X µl 4 µl 
Final volume 5 µl. 5 µl. 5 µl. 5 µl. 
The positive control was prepared as following: 
3.  1.2 Kb Kanamycin Positive Control RNA (1 µg)         2 µl 
4. Oligo (dT) Primer (0.5 µg/reaction)                               1 µl 
5.  Nuclease free-water                                                              2 µl   
6. The tubes were placed into a preheated 70°C heat block for 5 mins then 
immediately chilled in ice-water at least 5 mins. before centrifugation for 
10 seconds. 
7. Reverse transcriptase reaction mix was prepared as follows: 
Nuclease free water 5.7 µl 
ImPromII 5x Reaction Buffer 4.0 µl 
MgCl2 2.8 µl 
dNTP mix 1.0 µl 




Final volume 15 µl 
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8. 15 µl was added to 5 µl of each reaction sample and mixed together to make 
a final volume 20 µl. 
9. Using an Eppendorff Thermocyler the following protocol was followed:  
       a. Anneal: 25°C for 5 mins 
       b. Extend: 42°C for 1 hr. 
       c. Inactivate Reverse Transcriptase: 70°C for 15 mins. 
10. Then for PCR amplification the following primers used were: 
For conventional PCR and the following steps were followed. 
Preparation master mix of PCR was as follows: 
 
10X Dream Taq Buffer 5 µl 
dNTP mix 2mM 5 µl 
Forward primer 1 µl 
Reverse Primer 1 µl 
cDNA 1 µl 
Dream Taq DNA Polymerase 0.5 µl 
Nuclease Free water 36.5 µl 
Total volume 50 µl 
Cgβ-tubuline forward primer:  5′TAAAACGACGGCCAGTGAGC3′ 
Cgβ-tubuline reverse primer:    5′TCTCCTGGCGAGTGCTGC3′ 
CgLCB2 Forward primer:        5′CAGACAACTTTGTTTTCGG3′ 
CgLCB2 Reverse primer:          5′GGGTGGCATTGTAGGGC3′ 
CgSMS1Forward primer:         5′GCTCTTAGACATGATCGAGAC3′ 
CgSMS1Reverse primer:          5′CCAACTATGCAGAAAAATCTT3′ 
CgSMS2Forward primer:        5′AGCTTATCCAACGGGCTACG3′ 
CgSMS2Reverse Primer:         5′GAGTCTCCGTTGAGCTTCGG3′ 
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For LCB2, SMS1 and SMS2 primers and β-tubulin primers, 35 cycles of 
amplification in an Eppendorf thermocycler following the program: 
Process Time Temperature 
Initial denaturation 95°C 3 mins. 
Denaturation 95°C 30 sec. 
Annealing 55°C 30 sec. 
Extension 72°C 1 min. 
Final extension 72°C 15 mins. 
 
11. After PCR amplification, all the samples were separated on a 0.8% agarose 
gel in tris-acetate buffer. 
12.  For Real Time PCR the SYBR®Green Jump Start™ Taq ReadyMixä (SIGMA 
ALDRICH; Catalog number: S4438) was utilised following the manufacturer’s 
protocol and the Real Time Thermal cycler Rotor-Gene™ 3000 (Corbett 
Research).  
 
2.7 Metabolic labelling of Toxoplasma gondii, vero cells  
T. gondii RHΔHX tachyzoite infected vero cells were disrupted by passing through 
a narrow-gauge needle (23G) and the milieu filtered through 3 µm polycarbonate 
filters to remove contaminating host material (Weiss and Kim, 2007). T. gondii 
were isolated by centrifugation at 1430g for 15 minutes at room temperature, 
and then resuspended in DMEM without serum and counted using a Neubauer 
haemocytometer. 107 parasites were resuspended in 1ml of serum-free DMEM, 
washed twice, then incubated with 990 µl free serum medium and 10 µl of 
Aureobasidin A AbA (1 mg/ml) or its analogue Compound 20 (Cmpd20)                     
(1 mg/ml) for 1, 4 and 7 hours. After washing 2 times with serum-free DMEM, 10 
µl of 0.5 mM fluorescent NBD-C6-ceramide complexed to Bovine Serum Albumin 
(BSA) was added and the samples incubated at 37°C for 1 hour. T.  gondii 
tachyzoites were then pelleted by centrifugation and washed twice with DMEM, 
membrane lipids were then extracted by bi-phasic separation, 200 µl of 
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Chloroform : Methanol : Water (10:10:3 v/v/v) was added to the dry pellet and 
the samples were incubated overnight before the addition of 50 µl of water and 
the separation of the organic phase containing the extracted lipids. The organic 
solvent phase was concentrated in Rotavapor Eppendorf concentrator 5301 at 
30 °C for 20 minutes and the dried pellets resuspended in 20 ul for C:M:W 
10:10:3. Thin Layer Chromatography fractionation was then carried out using 
high performance (HP) TLC silica plates with a solvent phase of Chloroform : 
Methanol : 0.25% KCl (55:45:10 v/v/v) for 30 – 45 minutes. The plate was 
scanned by using the Fuji®FLA 3000 and analysed by AIDA Image FLA software.  
Vero cells were scraped from tissue culture flasks and washed twice with dH2O, 
then resuspended at 106/ml, and resuspended in 990 µl serum-free media and 
10 µl of Aureobasidin A AbA (1 mg/ml) or its analogue Cmpd20 (1 mg/ml), and 
incubated for 1, 4 and 7 hours at 37 °C and 5% CO2, then washed 2 times with 
serum-free DMEM. To monitor sphingolipid biosynthesis in vero cells, 10 µl of 
0.5 mM fluorescent NBD-C6-Ceramide complexed to BSA was added and the 
samples then incubated at 37°C and 5% CO2 for 1 hour. Cells were then pelleted 
by centrifugation and prepared and analysed as above.  
 
2.8 Metabolic labelling of Yeast 
YPH499 yeast cells were used in this experiment. A colony from an YPD agar plate 
was inoculated into YPD broth and grown in a shaking incubator at 30°C 
overnight. The cells were harvested by centrifugation at 1000g for 5 mins at 4°C, 
and resuspended in 990 µl YPD at a concentration of 2.5 OD 600nm. The cells 
were incubated for 1 hour at 30 °C, then 10 µl of Aureobasidin A AbA (1 mg/ml) 
or its analogue Cmpd20 (1 mg/ml) was added, and the cell further incubated for 
1, 4 and 7 hours at 30 °C.  10 µl of 0.5 mM fluorescent NBD-C6-Ceramide 
complexed to BSA was added then the cells were harvested again by 
centrifugation, washed twice with PBS, resuspended in 0.4 ml Chloroform: 
Methanol (1:1 v\v) and homogenized using acid washed glass beads 0.6 ml. 
Following centrifugation, the solvent phase was prepared and analysed as above. 
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2.9 Yeast susceptibility assay 
YPH499-HIS-GAL-AUR1 complemented with TgSLS or AUR1 (Denny et al., 2006; 
Pratt et al., 2013) were assayed for susceptibility to Aureobasidin A (AbA) and 
Cmpd20. The transgenic yeast strains were maintained on SGR -HIS -URA agar 
(0.17% Bacto yeast nitrogen base, 0.5% ammonium sulphate, 4% galactose, 2% 
raffinose, containing the appropriate nutritional supplements) at 30◦C. To 
analyse susceptibility to AbA and Cmpd20 plates containing 5 and 10 µg/ml of 
the compounds were prepared and 10 µl of an aqueous suspension of one yeast 
colony spotted onto the surface before incubation at 30 ◦C. 
 
 2.10 Study the effect of AbA and Cmpd20 on Toxoplasma gondii 
proliferation 
This experiment was designed to determine the 50% effective dose (ED50) of 
fungal inositolphosphoryl ceramide (IPC) inhibitors Aureobasidin A (AbA) and 
its analogue Cmpd20 on Toxoplasma gondii proliferation using a 96-well plate 
growth assay (Gubbels et al., 2002). In order to reduce the media fluorescent 
background, DMEM media without phenol red (Life technologies) was used in 
this experiment, 1% glutamine, 1% of sodium pyruvate, 1% penicillin/ 
streptomycin and 10% FCS were added to the media. 
The protocol as following: 
Day1: The primary cell line human foreskin fibroblasts (HFF) cells were seeded 
in black 96 black well plates, clear bottom with lid (Costar), concentration 1x105 
cell/ml in 100 µl DMEM media without phenol red. Cell incubated at 37°C and 5% 
CO2 for 24 hours.  
Day2: The media was removed, and the cells were washed with PBS, then T. 
gondii RH-HX-KO-YFP2-DHFR (Gubbels et al., 2002) tachyzoites at 6250 
parasite/well in 50 µl were added. 
Day3: The compounds (AbA and Cmpd20, in DMSO) in concentrations starting 
from 10 µg/ml and Equilibriate DMSO concentration were added in each well. 
Wells were washed at 1,4 or 7 hours with media if required. 
The plate was read every 24 hours for 7 days by using Synergy H4 Hybrid Reader 
(BioTek) excitation 510 and emission 540. 
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To measure the effect of the 2 compounds on T. gondii invasion the parasite cells 
were treated at the same range of concentration for 1,4 and 7 hours before 
infecting the HFF cells and proceeding as above. 
 
2.11 Toxoplasma gondii serine palmitoyltransferase 2 (TgSPT2) 
expression and purification 
The open reading frame of TgSPT2, lacking the first 158 amino acids, was codon 
optimised for E. coli, synthesized and cloned into the expression vector pOPIN3C 
by GenScript (figure 2-1). Rossetta II E. coli were transformed as above, with the 
plasmid pOPIN_HIS_SUMO_C3_TgSPT2. and selected on LB agar plates containing 
50µg/ml ampicillin and 17 µg/ml chloramphenicol. The plates were incubated at 
37°C overnight and a single colony added to 20 ml starter culture Power Broth 
(PB) media: prepared by adding PB broth 52g to 8 ml glycerol 50%, then the final 
volume 1 liter was prepared by adding high purify water, then autoclaved at 
121°C for 15 mins. After autoclaving, ampicillin to 50 µg/ml, chloramphenicol to 
17 µg/ml and 1% w/v glucose were added to this media. The cells were incubated 
at 37°C and 175 rpm overnight. After overnight incubation, 10 ml of starter 
culture was transferred into 500 ml Terrific Broth (TB) media culture: prepared 
by adding 30g TB broth to 10 ml glycerol 50%, then the volume filled up to 1 litre, 
the media autoclaved at 121°C for 15 mins, then ampicillin to 50 µg/ml and 
chloramphenicol to 17 µg/ml were added to this media. The culture was 
incubated at 37°C and 140 rpm until the optical density (O.D.) reached to OD600 
= 0.5, the growth was followed up by measuring 1 ml each hour, when the growth 
reached to this point the temperature was shifted down to 25°C and incubation 
continued for 22-24 hours, 140 rpm. The growth was then transferred to the 
centrifuge tube (500 ml), spun at 4000g at 4°C for 30 mins, the supernatant was 
discarded, and the pellets were weighed and stored in sterile 50 ml falcon tubes 
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2.11.1 Bacterial pellet lysis 
The pellets were thawed on ice, 2 ml of lysis buffer (50 mM Tris Base, 500 mM 
NaCl, 20 mM imidazole, 0.2% Tween 20 (v/v) at pH 7.5) was used to suspend the 
pellet by adding 2ml per 1 g pellet. 1 tablet of mini EDTA-free protease inhibitor 
was added per 15 ml, 50 mg/ml deoxyribonuclease (DNase) and 50 mg/ml 
ribonuclease (RNase) were added. The solution was mixed by vortex until the 
pellet was fully suspended. The suspension was sonicated with 2 pulses for 5 
mins (30 seconds sonication and 30 seconds on ice). The mixture was 
centrifugated at 42000g for 30 mins at 4°C in order to remove cell debris and 
insoluble fractions. The supernatant was then passed through a 0.22 µm filter to 
remove any debris. 
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2.11.2 Immobilised Metal Affinity Chromatography (IMAC) 
By using an AKTA Explorer Fast Protein Liquid Chromatography (FPLC), a HIS 
Trap FF 5 ml column (GE Helathcare) was first washed with water, then 
equilibrated with wash buffer (50 mM Tris Base, 500 mM NaCl, 20 mM imidazole, 
25 µM PLP, 5% glycerol (v/v) and pH 7.6. The supernatant from cell lysis was 
loaded onto the column via injection of the sample. An AKTA program was run to 
incrementally add elution buffer (50mM Tris Base, 500mM NaCl, 1M imidazole, 
25μM PLP, 5% glycerol (V/V), pH 7.6) to the IMAC column at a gradient of 0-
100%. 5ml protein containing fractions were collected and put together in one 
Vivaspin 20 (Generon) Falcon tube, centrifuged for 15 mins, and the protein 
concentration measured by Nanodrop (Thermo Scientific).  
 
2.11.3 Analyses of Protein 
The resultant protein was analysed by using Sodium Dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) at 180V, 400 mA for 1 hour., the 
solution and buffers used in this gel are as follows: 
 
2.11.3.1 Resolving solutions 
This solution was prepared as following: 30% acrylamide, resolving Buffer [187 
g Tris Base (1.5 M), pH 8.8 with HCL; 4g SDS (0.4%), dH2O to 1L], ammonium 
persulphate (APS) 10%, dH2O, TEMED. 
 
2.11.3.2 Stacking solutions  
This solution was prepared as following: 30% acrylamide, stacking Buffer [60.5 
g Tris Base; 4.0 g SDS (0.4%); dH2O to 1L], APS 10%, dH2O, TEMED. 
 
2.11.3.3 Staining solution 
This solution was prepared as following: methanol 50%, Glacial acetic acid 10%, 
Coomassie R25 0.25%. 
 
2.11.3.4 De-Staining solution 
This solution was prepared as following: methanol 30%, Glacial Acetic Acid 10%, 
dH2O. 
2.11.3.5 Running Buffer 10X  
This solution was prepared as following: Glycine [144g], SDS [10 g], Tris [30 g]. 
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2.11.4 TgSPT2 Activity Assay 
TgSPT2 activity assay was determined by production of 3-
ketodihydrosphingosine (KDS) by purified TgSPT2 from the substrates L-serine 
and palmitoyl CoA. By using a 3KDa MWCO slide-A-Lyzer dialysis cassette, 5.65 
mg/ml of purified HIS tagged TgPT2 was dialysed against activity assay buffer 
(50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM 
KCL,0.2 mM EDTA, 5% glycerol and 25 µM PLP) (Mina et al., 2017). After dialysis, 
1 ml activity assay solution was prepared in a glass vial by mixing 20 µM dialysed 
TgSPT2, 20 mM L-serine and 1.6 mM of palmitoyl Co-A. The solution was 
incubated for 75 mins at 37°C. After incubation, 1 ml of 2:1 CHCl3:CH3OH (v/v) 
was added to the activity assay solution, vortexed and centrifuged at 10000g for 
5 mins to separate aqueous and organic layers. The organic layer was extracted 
and evaporated by using the vacuum centrifuge at 5000g and 60°C. The residues 
were resuspended by adding 150 µl MeOH and KDS formation analysed using 
ultra-performance liquid chromatography (UPLC) electron spray ionisation (ESI) 
MS (Mina et al., 2017).  
 
2.11.5 TgSPT2 secondary structure prediction 
Easy Sequencing in PostScript (ESPript 3.0) (Gouet and Courcelle, 2003). In this 
study, Toxoplasma gondii was used as a model for the Apicomplexa. Toxoplasma 
gondii serine palmitoyltransferase (TgSPT), Eimeria tennela SPT, Plasmodium 
falciparum SPT, Plasmodium vivax SPT and Cryptosporidium muris SPT are similar 
to well-studied bacterial SPT from Sphingomonas paucimobilis (PDB: 2W8T) 
were analysed by using ClustalW Omega programme (Sievers and Higgins, 2014). 
 
2.12 TgSPT2 localisation 
The plasmid construct pG1TgSPT2_YFP was used for the detection of TgSPT2 co-
localised with markers for the Golgi apparatus (Golgi Reassembly Stacking 
Protein [GRASP] tagged with Red Fluorescent Protein [RFP] (Pfluger et al., 
2005)) and endoplasmic reticulum (ER retention signal HDEL tagged with Green 
Fluorescent Protein [GFP] (Boevink et al., 1999). The following steps describe the 
process: 
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2.12.1 Construction of the plasmid pG1TgSPT2_YFP 
TgSPT2 was cloned into pG27 using Ligation Independent Cloning (LIC) to tag 
the C-terminal with Yellow Fluorescent Protein (YFP) and form 
pG27TgSPT2_YFP.  TgSPT2_YFP was then subcloned, using the Infusion system, 
into pG1 which is designed for transient transfection 24-72 hr and expression 
under the control of the high level Tub8 promotor. 
 
2.12.1.1 TgSPT2 LIC primers 
The plasmid pG27 LIC-YFP-DHFR was used for YFP tagging TgSPT2 (Figure 2-2).  
The primer set to amplify TgSPT2 from a GenScript synthesized plasmid were 
designed for LIC cloning as following: 
The forward primer was engineered to contain a GC (bold) upstream of the ATG 
(underlined) start codon. 











2.12.1.2.A T4 processing protocol: 
2.12.1.2.A.1: PacI digest LIC vector (pG27-YFP-DHFR) : 
Plasmid pG27 LIC-YFP-DHFR Figure (2-2) was cut using the PacI restriction 
enzyme (5 units of enzyme/µg at 37°C overnight), then the Qiagen PCR 
purification kit was used to remove the enzyme and buffer. Complete 
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Figure (2-2) pG27 LIC-YFP-DHFR (generated by SnapGene)(provided by 
Markus Meissner, Glasgow University) 
 
YFP: yellow fluorescent protein 
DHFR: Dihydrofolate reductase 
 
2.12.1.2.A.2: T4 reaction: 
The reaction was prepared by following Novagen manual (T4 DNA Polymerase 
LIC qualified): 
Approximately 1.2-1.8 µg linear DNA was used, and 60 µl reaction was prepared 
as follows: 6 µl of 10x buffer, 3 µl of 100 mM DTT, 2.4 µl of 100 mM dGTP, 6.0 µl 
of template DNA (200-300 ng/µl), 1.5 µl of T4 DNA Polymerase, and 41.1 µl of 
dH2O. 
The reaction was mixed on ice, then using a 3Prime Techne PCR machine as 
following: the reaction incubated for 30 mins at 22°C, then shifted to 75°C for 20 
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2.12.1.2.B Insert (TgSPT2) 
The plasmid pU57 containing TgSPT2_TGGT1 open reading frame (ORF) 
provided by GeneScript was transformed into DH5α E. coli (as above) and 
transformants selected on LB agar with 50 µg/ml ampicillin. A single colony was 
inoculated into 5ml LB broth with 50 µg/ml ampicillin and incubated at 37°C 
overnight. Plasmid DNA was isolated using the Qiagen Miniprep Kit and 
concentration measured by Nanodrop. 
 
2.12.1.2.B.1 PCR using LIC primers (2.12.1.1) 
TgSPT2_TGGT1 was from the plasmid above following the Invitrogen Platinum 
Taq DNA Polymerase High Fidelity protocol in a 3Prime TECHNE PCR machine as 
following  
1. TgSPT2 template < 500 ng. 
2. 0.2 µM forward and reverse primers. 
3. 50 µl PCR reaction prepared as follows: 
Components  TgSPT2 PCR 
reaction (µl) 
- dH2O 38.8 
- 10x high fidelity buffer 5.0 
- 10 mM dNTP mix 1.0 
- 50 mM MgSO4 2.0 
- Platinum Taq DNA High Fidelty Polymerase 0.2 
- 10 µM forward primer 1.0 
- 10 µM reverse primer 1.0 
- Template DNA 1.0 
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4. PCR thermocycler 
Step Temperature (°C) Time 
Initial temperature 94 30s-2min 




Anneal  ~ 55 30s 
Extension  68 1 min/Kb 









5. Analyse 10 µl of reaction mix by agarose gel electrophoresis. 
6. The mixture was cleaned using a Qiagen Gel Extraction Kit, then DNA 
concentration measured by Nanodrop. 
 
2.12.1.2.B.2: T4 reaction 
By following the protocol provided by Markus Meissner (personal 
communication) the following steps were done: 
A. 20 µl reaction was prepared as follows:  
i. 2.0 µl 10x buffer 
ii. 1.0 µl 100 mM DTT 
iii. 0.8 µl 100 mM dCTP 
iv. 5.0 µl template DNA (200-300 ng/ µl) 
v. 0.5 µl T4 DNA Polymerase 
vi. 10.7 µl dH2O 
A. The reaction mixed gently on ice, and then incubated in the PCR machine 
as follows: 
i. Incubated for 30 mins at 22°C. 
ii. Shift to 75 °C for 20 mins. 
iii. Temperature reduced to 4°C. 
 
2.12.1.2.C Annealing  
1. 0.1 µl of treated vector and 0.2 µl treated insert were mixed on ice. 
2. The reaction was incubated at room temperature for 10 minutes. 
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3. 1 µl of 25 mM EDTA was added, and the reaction incubated for 5 minutes 
at room temperature. 
4. The temperature was reduced to 4°C. 
5. 1 µl was used to transform DH5α E coli as above. 
 
2.12.1.2.D pG27 TgSPT2_YFP mapping 
Following isolation of plasmid from transformants as above, restriction mapping 
was done using EcoR1 to confirm identity. 
 
2.12.3 Infusion cloning 
TgSPT2_ YFP was subcloned, using Infusion, from pG27 TgSPT2_YFP into the 
plasmid pG1 (Figure 2-3) to allow transient expression in T. gondii. expression. 
The Clontech InFusion HD Cloning guidance was followed:  
 
2.12.3.A  Preparation of linearized vector (pG1) 
The restriction enzymes (EcoRI and PacI) were used to cut pG1 plasmid, 
removing the GFP and TY tags and linearizing the plasmid. All digestion product 
separated on an agarose gel 0.8% as above. The DNA fragment was using the 
Qiagen gel extraction kit following the manufacturer’s instructions.  
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2.12.3.B PCR primer design and PCR 
InFusion primers must be designed in a way to use gene specific primers 
(TgSPT2YFP) containing extensions ends (15-18 bp) homologous to the ends of 
linearized vector (pG1). The following primers were used in this study: 
FORWARD 5'CATTTTTTCTTGAATTCAAATGTTCGGAAGCGTCTTTG'3 
REVERSE   5'GTGAGCACAACGGTGATTAATTAATTTACTTGTACAGCTCGTC'3 
Hi Fidelity PCR amplification for cloning was used in this study, CloneAmp HIFI 
PCR Mix following the manufacturer’s (Takara: Clontech) instructions:  







2. PCR machine programmed as following: 
Step Temperature (°C)  Time  
Initial temperature 94 30s-2min 
Denature  25-35 PCR 
Cycles 
98 15s 
Anneal  ~ 55 30s 
Extension  72 1 min/Kb 
Hold  4  
3. The product was run, as before, on a 0.8% agarose gel to check the 
amplification of the fragment (TgSPT2_YFP). 
 
2.12.3.C Infusion cloning reaction 
1. Infusion cloning reaction was prepared as following: 
CloneAMP HiFi PCR Premix 12.5 µl 
10 µM forward primer 5.0 µl 
10 µM reverse primer 5.0 µl 
pG27 TgSPT2_YFP  2.0 µl 
dH2O 0.5 µl 
5x In-Fusion HD enzyme 2 µl 
Linearized vector (50-200 ng) 2 µl 
Purified PCR fragment (TgSPT2_YFP) 4 µl 







2. The reaction was mixed well and incubated for 15 minutes at 50°C, then 
placed on ice. 
3. 2.5 µl of reaction was transformed into to 50 µl Stella E. coli cells (from 
kit) as directed. 
4. An individual colony was inoculated into 5 ml LB broth containing 50 
µg/ml ampicillin and incubated at 37°C overnight.   
5. Plasmid DNA was isolated by using Qiagen Miniprep Kit. 
6. Plasmid DNA was digested by using the restriction enzyme EcoRI to verify 
the new construct pG1TgSPT2_YFP. 
 
2.12.3.D pG1TgSPT2YFP sequence 
Following primers were used to sequence the constructed plasmid 
pG1TgSPT2_YFP: 
FWSPT21      TGT TCT AAC CAC GCA CCC TG  
RVSPT21       TGC CTC GGT TGT CCA ATC ATG TAG        
FWSPT22      GGC ATC AAG GTG AAC TTC AAG  
RVSPT22       CCG GTT AAC ACA ATT CTT GCC C  
FWYFP1        GCG GAC AAG AAA TAC GAA GTC        
RVYFP1        ACT TCT TCA AGT CCG CCA TGC C 
 
2.12.4 Electroporation 
4D-Nucleofector™ X Unit (Lonza) was used to transfect T. gondii RHΔHX with 
pG1TgSPT2_YFP and Plasmids for expression of GRASP_RFP and GFP_HDEL were 
used to label the Golgi and ER respectively. 
The AMAXA transfection protocol provided by Lonza was as follows: 
 
2.12.4.1 HFF and Toxoplasma gondii cell culture 
1. Fresh HFF cells were trypsinized from a T25 flask, and transferred to 24 
well plate with 13 mm coverslips, and the wells filled with 1 ml DMEM 
dH2O 2 µl 
Final volume 10 µl 
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containing 10 % FCS serum, and 1% penicillin/streptomycin. The plates 
were incubated at 37°C and 5% CO2 incubator until use, 3-5 days . 
2. Toxoplasma gondii tachyzoite infected HFF cells were scraped from a flask 
and parasites released by passage through a 23G needle.  Parasites were 
then separated from the host material using 3 µm Millipore polycarbonate 
filters, harvested by centrifugation at 1430g for 15 minutes, and 
resuspended by adding the desired volume of DMEM media.   
 
2.12.4.2 Nucleofection reactions  
Two reactions below were used in this experiment in order to know the TgSPT2 
subcellular-localization by using the co transfection with P30 CRASP_RFP (Golgi 
marker) and GFP_HDEL (ER marker) by following the AMAXA transfection 
protocol provided by LONZA: 
1. pG1TgSPT2_YFP (25 µg) + P30 GRASP_RFP (10 µg) 
2. pG1TgSPT2_YFP (25 µg) + P30 GFP_HDEL (10 µg) 
 
2.12.4.3 DNA  
1. Purified plasmid DNA was resuspended in 100 µl TE buffer. 
2. 11 µl of 3M sodium acetate (NaOAc) (pH5.2) was added. 
3. DNA was precipitated by adding 250 µl 100% ethanol and incubating at -
20°C for 20 minutes. 
4. DNA was pelleted by centrifugation at 9500g, 4°C for 30 minutes. 
5. The supernatant was discarded and the pellet washed in 500 µl 70% 
ethanol before pelleting as in 4 and air-dried by leaving the lid off in 
biosafety cabinet for 20-30 minutes. 
6. 107 parasites per reaction was pelleted by centrifugation and resuspended 
in 100 µl of P3 buffer (Nucleofector solution). This was then added to the 
dried DNA samples and transferred to an AMAXA cuvette. 
7. Nucleofector programme (FI-158, which is the specific program for 
Toxoplasma gondii transfection) was used. 
8. 300 µl pre-warmed DMEM media containing 10% FCS and 1% 
penicillin/streptomycin was added to the cuvette post transfection. 10 µl 
or 20 µl of this was transferred to 4 wells of a 24 well plate seeded with 
Chapter two: Materials and methods 
56 
 
HFF cells as described, and the cells then incubated for 48 or 24 hours 
respectively. 
 
2.12.5 Fixing cells 
1. The cells were washed with 500 µl volumes of PBS at room temperature. 
2. 300 µl of 4% paraformaldehyde (PFA) in PBS was added to each well, and 
incubated at room temperature for 15 minutes. 
3. The wells were washed with 500 µl PBS (3x5 minutes).  
 
2.12.6 Staining 
1. The cells were permeabilized with 0.4% (v/v) triton X-100 in PBS for 10 
minutes.  
2. Washed with PBS 3x for 5 minutes. 
3. After PBS washing (3x for 5 minutes), the cells were mounted using  4’,6-
Diamino-2-phenylindole dihydrochloride (DAPI) Fluoromount (Southern 
BioTech) to stain the nuclei. The edges were sealed with 2-layers of nail 
polish.   
4. Zeiss Apotome microscope was used to examine the protein localisation 
by using the filters (DAPI, Green, Rhodamine, and Yellow) and the 63X oil 
objective lens. 
5. For high resolution imaging, the Zeiss LSM 880 microscope with Airyscan 
was used with appropriate filters (Red, Yellow and Blue), and the 63X oil 
objective lens. 
 
2.13 TgSPT2 knockout (KO) 
2.13.1 KO Plasmid (pTub5CatSagF1F2) construction and mapping 
The plasmid that used in this study was pTub5CatSag1F1F2 (figure 2-4) 
(personal communication with Hosam Shams-Eldin and Philip Stahl/University 
of Marburg), a construct designed to knockout the 2 tandem copies of T. gondii 
SPT was made and supplied. This vector was transformed into the competent 
DH5α E. coli as described above.  
To map the vector, single digestions with restriction enzymes NotI and XhoI and 
double digestions with restriction enzymes NotI + XhoI and NotI + HindIII were 
performed. The protocol used in both single and double digestion was: 
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For single digestion: 
Plasmid DNA 1 µg/µl 0.5 µl 
Nuclease free water 15.5 µl 
Restriction enzyme 10x Buffer    2 µl 
Restriction enzyme 2 µl 
Total volume 20 µl 
 
For double digestion: 
Plasmid DNA 1 µg/µl 0.5 µl 
Nuclease free water 13.5 µl 
Restriction enzyme 10x Buffer    2 µl 
Restriction enzyme 1 2 µl 
Restriction enzyme 2 2 µl 
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2.13.2 Deletion of TgSPT1 and 2 by homologous recombination 
25 µg of pTub5CatSag1F1F2 was linearized by digestion with XhoI as above. 
Following ethanol precipitation this was transfected into T. gondii Δku80-HXG in 
the same manner as described for transient expression constructs. However, 20 
µM of chloramphenicol was added to the transfected cultures and resistant 
parasites selected after 3 rounds of egress. A mock transfection (no DNA) was 
used as a control.  
DNA extracted for RHKu80 (control), or RHdeltaKu80_SPTKO (expt) 
1. 1 × T75 culture plates infected HFFs, > 85% lysed 
2. Cells scratched, homogenised through a syringe 
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4. gDNA extracted using QIAamp DNA Mini Kit 
The primers below were designed to amplify the flank regions (XhoI and SacI) 
and CAT marker 
P1 (TgSPT 5' Flank A XhoI): CCCCTCGAGCCCTCCACACGCTGAATTTCG 
P4 (TgSPT 3' Flank B SacI): CCCGAGCTCTTGATCGCAACTTTCTGTGCAGTA 
P5 (CAT F): CCACCGTTGATATATCCC 
P6  (CAT R): GTAATTCATTAAGCATTCTGC 
Then 25 µl PCR reaction volume of each sample was prepared, and PCR machine 
programmed as follows: 
Step Temperature (°C) Time 
Denature 90 30s 
Anneal 64 30s 
Extension 72 9 s 
Final extension 72 10 min 
 
2.14 Metabolomics analyses 
Leishmania major was used as model to study the global effect of inhibiting 
Inositol Phosphorylceramide Synthase (IPCS). IPCS is a non-mammalian enzyme 
found in sphingolipid biosynthesis pathway in this parasite. It is a potential drug 
target in Leishmania spp. and other protozoa, including apicomplexan parasites 
such as T. gondii.  
Two compounds, clemastine and a benzazepine (CMPD35), already identified as 
an IPCS inhibitors were used against the L. major Friedlin Virulent (FV1) strain 
(wild type [WT]) to study the effect of these compounds and IPCS inhibition on 
the metabolome of the parasite.  
Also, we studied the metabolomic effects of miltefosine (the only oral therapy for 
treatment of leishmaniasis; Croft and Engel, 2006) on L. major FV1 (WT) and a 
mutant strain (MT) L. major ∆LCB2 (Denny et al., 2006), which lacks the ability 
to synthesize sphingolipid. 
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2.14.1 Effect of clemastine and benzazepine (CMPD35) on Leishmania 
major FV1 metabolome 
2.14.1.1 Half time to cell death assay 
The stocks for both compounds (10 mM) were prepared in Dimethylsulfoxide 
(DMSO). Assays were prepared in sterile 24 well-plates. In each well the 
compounds were diluted to 2x the desired concentrations of 10µM and 5 µM 
(triplicates) for clemastine, and 80 µM and 40 µM (triplicates) for the 
benzazepine, in 500 µl of Schneider’s media supplemented with 10% heat-
inactivated FCS, and 1% penicillin/streptomycin. Then 500 µl of L. major FV1 
promastigotes at a concentration 1x107/ml were added to each well, to give a 
final volume of 1 ml/well. The plate was incubated at 26°C and morphology and 
numbers of parasite were examined at 20, 24 and 42 hours. 
 
2.14.1.2 Cell extraction for metabolomics 
From previous experimentation (2.13.1.1), the best time for metabolomic 
analyses was after 42 hours with 10 µM of clemastine and 40 µM of the 
benzazepine, CMPD35. At this time point the WT parasite morphology changed 
from an elongated to a round shape but maintained viability. Promastigote L. 
major FV1 (5x107 cells at 5x106/ml) were seeded into T25 tissue culture flasks 
containing Schneider’s medium supplemented with 10% heat-inactivated FCS, 
and 1% penicillin/streptomycin, in triplicate for each sample. Each compound 
was added to the required concentration and an equivalent volume of DMSO was 
added to control flasks as following: 
 
Groups Addition 
Leishmania major FV1 + Clemastine (10 mM) 10 ml + 10 µl + 30 µl DMSO  
Leishmania major FV1 + CMPD35 (10 mM)  10 ml + 40 µl 
Leishmania major FV1 + DMSO (100%) 10 ml + 40 µl 
 
After incubation at 26°C for 42 hours, the promastigotes were counted in all 
flasks and 5x107 cells were prepared from each sample for metabolomic 
extraction, following the protocol below provided by Mike Barrett (Glasgow) 
(personal communication): 
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1. 5x107 cells per each sample (3 replicates) were harvested in logarithmic 
phase by centrifugation at 1430g for 15 minutes. 
2. The temperature was quenched rapidly using a dry ice/ethanol bath and 
mixing vigorously to avoid the freezing and cell lysis. 
3. The samples were kept on ice, then centrifuged at 1250g for 10 minutes 
at 4°C. 
4.  The supernatant was discarded and 1 ml left in which to resuspend the 
cells. 
5. The cells were transferred to an Eppendorf tube, and centrifuged at 2260g 
for 10 minutes at 4°C, all the medium was then removed. 
6. The cells were washed, and resuspended with 1 ml PBS at 4°C. Centrifuged 
at 2260g for 10 minutes at 4°C and all PBS removed. 
7. The pellet resuspended by adding 200 µl extraction solvent 
(Chloroform:Methanol:Water (CMW) 1:3:1 v/v/v) at 4°C and mixing well. 
8. 200 µl CMW sample was prepared as a blank.   
9. The samples left on a shaker incubator at max speed in the cold room (4°C) 
for 1 hour. 
10. Samples were centrifuged at 18890g for 10 minutes at 4°C.     
11. 180 µl was taken from the supernatant and placed into screw-top vial, 20 
µl was taken from each sample and mixed together in a one vial tube to 
used it as a quality control (QC). 
12. Argon was added to each sample before storing at -80°C until analyses by 
liquid chromatography-mass spectrometry (LCMS).   
13. The samples analysed by Erin Manson at the Glasgow Polyomics Research 
Centre. 
14. The metabolomic data was evaluated using IDEOM in an Excel template 
(Creek et al., 2012). 
 
2.14.2 Screening the efficacy of miltefosine against Leishmania major FV1 
(WT) and Leishmania major ∆LCB2 (MT) 
L. major FV1 and L. major ∆LCB2 were inoculated into fresh Schneider’s medium 
supplemented with 10% FCS and 1% penicillin/streptomycin at 1x106 
parasites/ml in a 96 well plate (50 µl each well). Serial dilutions of miltefosine at 
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100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM and 3.125 µM, prepared from a 
miltefosine stock solution in ethanol (10 mM), were made as following. The 
compounds were prepared at 2x concentration in triplicate, ethanol alone was 
added to the negative control by prepare 200 µM in 700 µl ethanol, then add 350 
µl from this tube and added to the next tube already have 350 µl media, mixed 
well to get 100 µM, same to prepare the other concentrations (figure 2-5).   
Then 50 µl of desired concentration was added to each well, containing 50 µl of 
parasites, to give a final volume of 100 µl. The plates were incubated at 26°C for 
different periods of time (figure 2-5).  






          200 µM                 100 µM               50 µM                   25 µM               12.5 µM                6.25 µM 
After 48 hrs incubation, Alamar Blue was used for detection of cell viability, (it 
allows measurement of reduction-oxidation (redox) reactions). 10 µl of Alamar 
Blue was added to each well and incubated for 4 hrs at 26°C, cell viability was 
monitored by changing color from blue (oxidation state) to pink (reduction state) 
(Rampersad, 2012). In addition, fluorescence changes were measured using 
FLx800 Fluorescent Reader (BioTek) plate reader (Excitation 540/35, Emission 
600/40). The data was analysed by using Excel. The effective Dose for 50% 
cytotoxicity (ED50) was calculated using Prism 7 software (GraphPad).     
            
2.14.3 The effects of miltefosine on the Leishmania major FV1 (WT) and 
Leishmania major ∆LCB2 (MT) metabolome* 
This experiment was designed to determine the mechanism of action of the drug 
miltefosine through analyses of changes to the parasite (WT and MT) 
metabolome. 1X ED50 (WT) and 3X ED50 (WT) concentrations against WT and MT 
L. major were used for 72 hours as follows: 
 
700 µl 350 µl Media 
350 µl 350 µl 350 µl 350 µl 350 µl 
350 µl 
350 µl Media 350 µl Media 350 µl Media 350 µl Media 
*Collaboration with Emily Armitage and Mike Barrett 
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 L. major FV1 and L. major ∆LCB2 promastigotes were inoculated in Schneider’s 
medium supplemented with 10% FCS without penicillin/streptomycin. All 
samples were grown and harvested in the logarithmic phase and counted. 5x107 
cells was prepared for each sample. The samples were divided into 6 groups, each 
group had 6 replicates as following: 
6 replicates with 1 x ED50 (10 µM) concentration of drug (WT) 
6 replicates with 3 x ED50 (30 µM) concentration of drug (WT) 
6 replicates with 1 x ED50 (10 µM) concentration of drug (MT) 
6 replicates with 3 x ED50 (30 µM) concentration of drug (MT) 
6 replicates with DMSO control (WT) 
6 replicates with DMSO control (MT) 
The samples were incubated with miltefosine or DMSO for 5 hours at 26°C, then 
the parasites counted and 5x107 parasites collected. The work flow is given 
below: 
1. The samples were centrifuged at 1500g for 10 minutes at 4°C.   
2. The supernatant was discarded, and 2 ml PBS was added to each sample, 
and mixed well. 
3. The sample was transferred to cryovials tube, centrifuged for 15 mins at 
1500g at 4°C.   
4. The supernatant was discarded and 200 µl ice cold 100% methanol added, 
and samples stored at -80°C until use.   
5. All the samples were analyzed by GlaxoSmithKline Espaňa (GSK). 
 
2.15 Lipidomic analyses 
This experiment was designed with collaboration with Terry Smith (University 
of St. Andrews), to analyze the effect of clemastine and the benzazepane 
(CMPD35) on the lipid profile of Leishmania major FV1. 
 
2.15.1 The effect of clemastine and benzazepane (CMPD35) on the lipid 
profile of Leishmania major FV1 
 L. major FV1 promastigotes were inoculated into Schneider’s medium 
supplemented with 10% FCS with 1% penicillin/streptomycin. 5x107 cells per 
Chapter two: Materials and methods 
64 
 
sample were divided into three T25 flasks each with 10 ml of media, clemastine 
or CMPD35 were added at concentrations of 10 µM and 40 µM, DMSO was added 
as a control:  
              a. L. major FV1 + 40 µl DMSO (control) 
b. L. major FV1 + 40 µM CMPD35 DMSO 
c. L. major FV1 + 10 µM clemastine + 30 µl DMSO 
d. L. major FV1 + 5 µM clemastine + 35 µl DMSO 
e. L. major FV1 + 1 µM clemastine + 39 µl DMSO 
f. L. major FV1 + 0.5 µM clemastine + 40 µl DMSO 
g. L. major FV1 + 0.1 µM clemastine + 40 µl DMSO 
All flasks were incubated at 26°C for 42 hours.   
 
2.15.2 Lipid extraction from Leishmania major FV1 (WT) (Bligh and Dyer 
1959) 
1. Leishmania major FV1 promastigotes were counted to prepare 108 cells in 
logarithmic phase for each sample. Cells were harvested by centrifugation 
at 800g for 10 minutes.  
2. The pellet was then resuspended in 1 ml PBS, and divided into four 250 µl 
samples in glass tubes. 
3. 930 µl of 1:2 Chloroform:Methanol (v/v) was added and the samples 
vortexed vigorously for 15 minutes. 
4. 312.5 µl of chloroform was added, then vortexed for 5 minutess. 
5. 312.5 µl of dH2O was added, then vortexed for 5 minutes. 
6. After Centrifugation at 1000g, room temperature for 15 minutes 2 layers 
were apparent. The top, which is aqueous layer, and bottom one which is 
the organic or lipid layer. 
7. The organic or lipid layer was transferred to a new glass vial using a glass 
Pasteur pipette. 
8. This layer was dried under N2, and stored at 4 ̊c until use. 
9. The samples were sent to Terry Smith (University of St Andrews) for analysis 
of the lipid profile by using electron spray-mass spectrometry (ES-MS) and 
gas chromatography-mass spectrometry (GC-MS). 
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2.16 Bioinformatic tools 
2.16.1 BLAST  
Using the two candidate TgSPT protein sequences previously identified in 
toxoDB.org (Mina et al, 2017) a BLAST search was performed against the 
National Center for Biotechnology Information (NCBI) database using default 
settings (Mount, 2007).  
 
2.16.2 ClustalW Omega 
Identified sequences were aligned using ClustalW Omega with output format 
(Sievers and Higgins, 2014).  
 
2.16.3 Phobius tool 
The transmembrane domains of TgSPT1 and TgSPT2 were predicted using 
Phobius. The parameters were set with long graphics (Käll and Sonnhammer 
2004).  
 
2.16.4 Hydrophobicity profile 
The hydrophobicity/hydrophilicity of TgSPT1 and TgSPT2 using Hphob. (Kyte and 
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3.1 Bioinformatic analyses of the T. gondii serine palmitoyltransferase 
Bioinformatics is an intradisciplinary scientific field includes molecular biology, 
biochemistry and genetics with computer science to study the protein functions and 
properties (Luscombe et al., 2001; Bai et al., 2012).  Bioinformatic analyses is 
dependent on three types of data: 
A. DNA or protein sequence. For DNA this includes the detection of coding and 
non-coding regions, i.e determination of the number of exons and introns. For 
protein sequence, this includes the identification of conserved sequence 
motifs and functional prediction (Luscombe et al., 2001). 
B.  Macromolecular structure. Showing the protein properties such as secondary 
or tertiary protein structure, protein-protein interactions, biochemical data, 
phylogenetic analysis and metabolic pathways (Luscombe et al. 2001). 
C. Functional genomic experiments results including gene expression (Luscombe 
et al., 2001).  
All the information above is available in EupathDB (http://eupathdb.org/eupathdb/), 
a group of databases for many organisms including AmoebaDB, CryptoDB, FungiDB, 
MicrosporidiaDB, PiroplasmaDB, PlasmoDB, TrichDB, TriTrypDB, OrthoMCL and 
finally ToxoDB (Madrid-Aliste et al., 2009; Weiss et al., 2009). ToxoDB is specified to 
provide genetic information and functional data bases for the T. gondii genome which 
consists of 14 chromosomes, and is about 63 Mb (Khan et al., 2005 ; Gajria et al., 
2007). ToxoDB also provides a gateway to the annotation and genome sequence and 
function of the T. gondii strains GT1 and RH (Type I), ME49 (Type II) and VEG (Type 
III). ToxoDB is used in this study to analyses an important enzyme catalysing the first 
step in the de novo T. gondii sphingolipid biosynthesis pathway, serine 
palmitoyltransferase (SPT). T. gondii have two closely related encoded SPTs, TgSPT1 
and TgSPT2.  
In this chapter, we will use bioinformatic tools and ToxoDB to predict the gene 
function, origin of the gene (bacterial or eukaryotic), transmembrane domains, 
expression levels and hydrophobicity/hydrophilicity for TgSPT1 and TgSPT2 
(http://www.toxodb.org).   




3.2 Gene information 
Serine palmitoyltransferase (SPT; E.C. 2.3.1.50) belongs to the pyridoxal phosphate 
α-oxoamine synthase family (Hanada, 2003 ; Hornemann et al., 2009). This family 
includes enzymes which catalyse the condensation of a particular amino acid (a.a.) 
with an acyl-CoA thioester substrate (Eliot and Kirsch, 2004; Yard et al., 2007).  
SPT is catalyses the first step in the sphingolipid biosynthesis pathway, the 
condensation of L-serine with palmitoyl Co-A to produce 3-ketodihydrosphingosine 
(3-KDS) (Lowther et al., 2012; Beattie et al., 2013). From ToxoDB, two potential T. 
gondii SPTs, TgSPT1 and TgSPT2 (68% identical), were identified previously (Mina et 
al., 2017). 
 
3.2.1 TgSPT1  
The gene ID within ToxoDB is TGGT1_290980, this gene is located on the 
chromosome IX, spanning the area between nucleotide 3,815,226 and 3,817,238. The 
gene is predicted to have 2 exons, exon 1 3,815,226 to 3,816,330 and exon 2 
3,816,588 to 3,817,238, and 1 intron, 3,816,331 to 3,816,587 (figure 3-1). The 
predicted encoded protein is 571 a.a. with a molecular weight 63.6 KDa.  
Figure (3-1) TgSPT1 model showing the exon and intron areas from (ToxoDB.org) 
 
In ToxoDB most of data for gene expression are from the Type II ME49 strain. Using 
the Blast protein tool (Mount, 2007), TgSPT1 from ME49 (TGME49_290980) was 
shown to have 100% identity with the predicted protein from GT1 (TGGT1_290980) 
therefore the expression data from type II T. gondii (TGME49_290980) was analysed 
here and below with confidence that it relates to other strains (figure 3-3).  
 




3.2.2 TgSPT2   
The gene ID within the ToxoDB is TGGT1_290970, this gene is located on 
Chromosome IX, nucleotide 3,811,046 to 3,812,950. The gene is predicted to have 
have 2 exons, the first from 3,811,046 to 3,812,128 and, the other from 3,812,300 to 
3,812,950, and 1 intron, 3,812,129 to 3,812,299 (figure 3-2).  The predicted encoded 
protein is 577 a.a with a molecular weight of 64.7 KDa. 
Figure (3-2) TgSPT2 model showing the exon and intron areas from (ToxoDB.org) 
Like TgSPT1, using Blast the predicted protein sequence from type I GT1 T. gondii was 
shown to be 100% identical to that in type II ME49 (TgME49_290970) (figure 3-3). 
Figure (3-3) Alignment sequence of TGGT1_290980 and TGME49_290980 (TgSPT1); 
and TGGT1_290970 and TGME49_290970 (TgSPT2). Each is 100% identical to its 
counterpart in the other strains. 
TGGT1_290970       -MFGSVFVLDSDPMGFIGNRNVEWTTNLDFFYCAFFSASLLGVLLAFFTDDVSSGSLRWS 59 
TGME49_290970      -MFGSVFVLDSDPMGFIGNRNVEWTTNLDFFYCAFFSASLLGVLLAFFTDDVSSGSLRWS 59 
TGGT1_290980       MASGATYFTRGTGSPFL-GAGVEWASNIDLFLCAFLSASVLGILLAFFNDEVSWGSLRWS 59 
TGME49_290980      MASGATYFTRGTGSPFL-GAGVEWASNIDLFLCAFLSASVLGILLAFFNDEVSWGSLRWS 59 
                      *:.:.  .    *: . .***::*:*:* ***:***:**:*****.*:** ****** 
TGGT1_290970       WIVMELLPVPRLSNHVAVKDVEGALITAAKQASGKSQVFAKIVTAAHEGTLKVLLAQWCT 119 
TGME49_290970      WIVMELLPVPRLSNHVAVKDVEGALITAAKQASGKSQVFAKIVTAAHEGTLKVLLAQWCT 119 
TGGT1_290980       WIATQLLPITPCSSHAVYKDVETALAKAARNKAGSKRALEEFLAALQDGTVMVLLSKWSA 119 
TGME49_290980      WIATQLLPITPCSSHAVYKDVETALAKAARNKAGSKRALEEFLAALQDGTVMVLLSKWSA 119 
                   **. :***:   *.*.. **** ** .**:: :*..:.: ::::* ::**: ***::*.: 
TGGT1_290970       KLHLRCWFCWHTLKLRYTAESRRQLLYQVNKVLLRLENRKGEKEVQSYLDIKRYMQTNNL 179 
TGME49_290970      KLHLRCWFCWHTLKLRYTAESRRQLLYQVNKVLLRLENRKGEKEVQSYLDIKRYMQTNNL 179 
TGGT1_290980       RGFERLAFYWQALKIKYTAQSRRQFFYQMQKVQLKLEIKPGETEMQSYNDAKRYMKSRDL 179 
TGME49_290980      RGFERLAFYWQALKIKYTAQSRRQFFYQMQKVQLKLEIKPGETEMQSYNDAKRYMKSRDL 179 
                   : . *  * *::**::***:****::**::** *:** : **.*:*** * ****::.:* 
TGGT1_290970       WYFAFRISDVKSQYITCEGKRAYHMSSYSYLDFMREPLVQEAALAAGRMWSTGNHGARML 239 
TGME49_290970      WYFAFRISDVKSQYITCEGKRAYHMSSYSYLDFMREPLVQEAALAAGRMWSTGNHGARML 239 
TGGT1_290980       WPFAYEVSNVKDTQVICEGVRAYPMSSYSYLDFVREPLVQEAALAAGRTWSTGNHGARML 239 
TGME49_290980      WPFAYEVSNVKDTQVICEGVRAYPMSSYSYLDFVREPLVQEAALAAGRTWSTGNHGARML 239 
                   * **:.:*:**.  : *** *** *********:************** *********** 
TGGT1_290970       GGNPTVIRELEQIIGRFFGREDALLCATGFLAAMSSICAVAKKGDLIIGDNRLHTSLRVG 299 
TGME49_290970      GGNPTVIRELEQIIGRFFGREDALLCATGFLAAMSSICAVAKKGDLIIGDNRLHTSLRVG 299 
TGGT1_290980       GGNMRILRDLEKMVGRFFGREDSLLCATGFLATMSSICAVAKEGDLIVGDNRLHASLRSG 299 
TGME49_290980      GGNMRILRDLEKMVGRFFGREDSLLCATGFLATMSSICAVAKEGDLIVGDNRLHASLRSG 299 
                   ***  ::*:**:::********:*********:*********:****:******:*** * 
TGGT1_290970       MKLSGAKEVLFRHNNWQHLTQILGSMRRKYIDCWIVIESVYSMDGDIADLPTVRRLADQY 359 
TGME49_290970      MKLSGAKEVLFRHNNWQHLTQILGSMRRKYIDCWIVIESVYSMDGDIADLPTVRRLADQY 359 
TGGT1_290980       MKLSGAKEMLFRHNNWHHLQQTLAKHRRKYKNCWIVIESVYSMDGDIADLPVVRRLADQY 359 
TGME49_290980      MKLSGAKEMLFRHNNWHHLQQTLAKHRRKYKNCWIVIESVYSMDGDIADLPVVRRLADQY 359 
                   ********:*******:** * *.. **** :*******************.******** 
TGGT1_290970       KCQIIVDEAHGLGVLGKSGRGLEEHFNMPGAADIIVGTFSKSIGGVGGFITCGKDLIEFL 419 
TGME49_290970      KCQIIVDEAHGLGVLGKSGRGLEEHFNMPGAADIIVGTFSKSIGGVGGFITCGKDLIEFL 419 
TGGT1_290980       NCRILLDEAHGLGVLGKTGRGLEEHFNMPGAADVIVGTFSKSIGGVGGYITGDNDLVEFL 419 
TGME49_290980      NCRILLDEAHGLGVLGKTGRGLEEHFNMPGAADVIVGTFSKSIGGVGGYITGDNDLVEFL 419 
                   :*:*::***********:***************:**************:** .:**:*** 
TGGT1_290970       EYHALGSVFSAPLTAYSAGGAKKAFELMQGEHRWRIAKAQENAIYLRRALKTGNGNWPPD 479 
TGME49_290970      EYHALGSVFSAPLTAYSAGGAKKAFELMQGEHRWRIAKAQENAIYLRRALKTGNGNWPPD 479 
TGGT1_290980       DFHAPGSVFSAPLTAYSAGGAMMAFELMQGEQSWRIAKAQENAKYLRHALQTGLGLWPKD 479 
TGME49_290980      DFHAPGSVFSAPLTAYSAGGAMMAFELMQGEQSWRIAKAQENAKYLRHALQTGLGLWPKD 479 
                   ::** ****************  ********: ********** ***:**:** * ** * 
TGGT1_290970       YPADKKYEVEGIECTTVIPVVFPNDPYRLCCVTRALFSKGWVVGAAMYPACPLMRPRIRI 539 




TGME49_290970      YPADKKYEVEGIECTTVIPVVFPNDPYRLCCVTRALFSKGWVVGAAMYPACPLMRPRIRI 539 
TGGT1_290980       YPAERKFELEGVACTTVIPVVFPHDGDRVFRVTQAMLKRGWMVAAAAYPACPLNRPRIRV 539 
TGME49_290980      YPAERKFELEGVACTTVIPVVFPHDGDRVFRVTQAMLKRGWMVAAAAYPACPLNRPRIRV 539 
                   ***::*:*:**: **********:*  *:  **:*::.:**:*.** ****** *****: 
TGGT1_290970       TATAAYTKEIMDKFVRDLVKTTVDVPLTTEVEDGPITL 577 
TGME49_290970      TATAAYTKEIMDKFVRDLVKTTVDVPLTTEVEDGPITL 577 
TGGT1_290980       TATAAYNQKMMDEFVKSLVEVTVECPPTDMLR------ 571 
TGME49_290980      TATAAYNQKMMDEFVKSLVEVTVECPPTDMLR------ 571 
                   ******.:::**:**:.**:.**: * *  :.   
     
 
3.3 Gene Expression 
ToxoDB was used to the expression profiles of TgSPT1 and TgSPT2 in oocyst, 
tachyzoite and bradyzoite ME49 T. gondii (figure 3-4).   
The expression profiles showed that TgSPT1 (figure 3-4a) expression is approximately 
equal in oocyst and tachyzoite, however, its expression is lower in bradyzoite. In 
contrast, TgSPT2 expression (figure 3-4B) in bradyzoite forms is higher than in oocyst 
and tachyzoite. This showed that TgSPT1 in predominant in tachyzoite, and TgSPT2 
is predominant in bradyzoite. Perhaps a specific type of sphingolipid or substrate is 
required for each stage, and T. gondii regulates sphingolipid biosynthesis depending 
on environmental conditions or lifecycle stage. Until now no information is available 
for the role of sphingolipids in T. gondii and more study is needed. Metabolomic 
analyses could be of benefit, for example analysing mutant strains lacking SPT1 and 
SPT2. 
 
Figure (3-4) Gene expression profiles for TgSPT1 and TgSPT2 in T. gondii life cycle 
stages. 
 A.                                                                                    B. 
 
 




3.4 Gene origin 
SPT is found in both eukaryotic and prokaryotic organisms, it is a membrane-bound 
heterodimeric enzyme in eukaryotes such as humans and yeast, and a cytoplasmic 
homodimeric enzyme in prokaryotes (Yard et al., 2007). In both cases the active site 
contains a pyridoxal phosphate (PLP) co-factor bound to a lysine residue as an 
internal aldimine (Shiff base) (Hanada, 2003; Yard et al., 2007). 
In humans, SPT consists of hSPT1 (HsLCB1), and either hSPT2 (HsLCB2) or hSPT3 
(HsLCB3) (Ikushiro and Hayashi, 2011 ; Genin et al., 2016). hSPT2 and hSPT3 subunits 
have catalytic activity due to the presence of lysine residue, whereas hSPT1 is 
believed to play a regulatory role due to its lack of PLP binding ability. The hSPT3 
subunit has only been found in mammals, birds, and lower vertebrates (Hornemann 
et al., 2009). Similarly, to humans, in yeast such as Saccharomyces cerevisiae, SPT 
consists of regulatory SPT1, which like hSPT1 lacks the active site lysine residue, and 
catalytic SPT2 which contains the active site lysine residue (Yard et al., 2007). 
In the Prokaryota, Sphingomonas paucimobilis is a Gram-negative bacteria 
characterised by having an outer membrane containing glycosphingolipid instead of 
lipopolysaccharide, and SPT catalyses the first step in glycosphingolipid biosynthesis. 
Overcoming difficulties analysing the bound-bound eukaryotic enzyme, Ikushiro et al. 
(2001) isolated the water-soluble SPT enzyme from S. paucimobilis. In this bacterium, 
SPT is a homodimer enzyme composed of 2 subunits of SpSPT with 2 active sites - one 
for each subunit (Yard et al., 2007). Like the eukaryotes, the active site is Lysine 
residue (Lys265), and a Histidine residue (His234) has been shown to be involved in 
PLP binding (Yard et al., 2007). This well studied protein it is now used as a model to 
determine the origin of TgSPT1 and TgSPT2. Using the ClustalW Omega tool 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) the eukaryote SPT sequences (human 
[Homo sapiens] (Hs) and yeast [Saccharomyces cerevisiae] (Sc)) and prokaryote SPT 
sequence [Sphingomonas paucimobilis] (Sp) were aligned with TgSPT1 and TgSPT2 









Figure (3-5) ClustalW for SPT alignment in eukaryotic (human and yeast) and 
bacterial SPT sequences. The conserved active residue site highlighted with 
turquoise (lysine), the conserved residue (histidine) involved in PLP binding 
highlighted with red. SpSPT (GenBank: BAB56013.1), HsLCB1 (GenBank: 
AAH68537.1), HsLCB2 (NCBI Reference Sequence: NP_004854.1), HsLCB3 (NCBI 
Reference Sequence: NP_001336874.1), ScLCB1 (UniProtKB-P25045), ScLCB2 
(UniProtKB-P40970), TgSPT1 (ToxoDB gene ID: TGGT1_290980) and TgSPT2 
(ToxoDB gene ID: 290970).  
SpSPT       ------------------------------------------------------------  0 
HsLCB1      ---------------------------------------------------MATATEQWV 9 
HsLCB2      --------MRPEPGGCCCRRTV------------------------RANGCVANGEVRNG 28 
HsLCB3      --------MANPGGGAVCNGKL------------------------HNHKKQSNGSQSRN 28 
ScLCB1      --------------------------------MAHI-PEVLPKSIPIPAFIVTTSSYLWY 27 
ScLCB2      ------------------------------------------------------MSTPAN 6 
TgSPT1      MASGATYFTRGTGSPFL-GAGVEWASNIDLFLCAFLSASVLGILLAFFNDEVSWGSLRWS 59 
TgSPT2      -MFGSVFVLDSDPMGFIGNRNVEWTTNLDFFYCAFFSASLLGVLLAFFTDDVSSGSLRWS 59 
                                                                         
SpSPT       ------------------------------------------------------------ 0 
HsLCB1      LVEMVQ-----------------------A--------------------LYEAPAYHLI 26 
HsLCB2      YVRSSA-AAAAAAAAGQIHHV-------TQ--NGGLYK------RPFN-EAFEETPMLVA 71 
HsLCB3      -----------CTKNGIVKEA-------QQNGKPHFYD------KLIV-ESFEEAPLHVM 63 
ScLCB1      YFNLVL-----------------------TQIPGGQFI------VSYIKKSHHDDPYRTT 58 
ScLCB2      YTRVPL-----CEPEELPDDIQKENEYGTLDSPGHLYQVKSRHGKPLPEPVVDTPPYYIS 61 
TgSPT1      WIATQLLPITPCSSHAVYKDVETALAKAARNKAGSK-R----ALEEFL-AALQDGTVMVL 113 
TgSPT2      WIVMELLPVPRLSNHVAVKDVEGALITAAKQASGKS-Q----VFAKIV-TAAHEGTLKVL 113 
                                                                         
SpSPT       ---------------------MTEAAA------------------QPHALPADAPDIAPE 21 
HsLCB1      LEG-----ILILWIIR-----LLFSK-----TY--------KLQERSDLTVKEKEELI-- 61 
HsLCB2      VLTYVGYGVLTLFGYLRDFLRYWRIEK-----------------CHHATEREEQKDFVS- 113 
HsLCB3      VFTYMGYGIGTLFGYLRDFLRNWGIEK-----------------CNAAVERKEQKDFVP- 105 
ScLCB1      VEI-----GLILYGII-----YYLSKP-QQKKS--------LQAQKPNLSPQEIDALI-- 97 
ScLCB2      LLTYLNYLILIILGHVHDFLGMTFQK-------------------NKHLDLLEHDGLAP- 101 
TgSPT1      LSKWS----------ARGFERLAFYWQALKIKYTAQSRRQFFYQMQKVQLKLEIKPG--- 160 
TgSPT2      LAQWC----------TKLHLRCWFCWHTLKLRYTAESRRQLLYQVNKVLLRLENRKG--- 160 
                                                         .      :        
SpSPT       RDLLSKFDGLIAERQK--------LLDSGVTDPFAIVMEQVKSPTEAVI----------- 62 
HsLCB1      ----EEWQPEPLVPPVPKDHPALNYNIVSGP--PSH-----------------KT----- 93 
HsLCB2      --LYQDFENFYTRNLYMRIRDNWNRPICSVPGARVDIMERQSHDYNWSFKYTG------- 164 
HsLCB3      --LYQDFENFYTRNLYMRIRDNWNRPICSAPGPLFDLMERVSDDYNWTFRFTG------- 156 
ScLCB1      ----EDWEPEPLVDPSATDEQSWRV--AKTP--VTMEMPIQNH----------ITITRNN 139 
ScLCB2      --WFSNFESFYVRRIKMRIDDCFSRPTTGVPGRFIRCIDRISHNINEYFTYSG------- 152 
TgSPT1      ---ETEMQSYNDAKRYMKSRDL------------------------WPFAYEVSNVKDTQ 193 
TgSPT2      ---EKEVQSYLDIKRYMQTNNL------------------------WYFAFRISDVKSQY 193 
                 . :  
SpSPT       ---RGKDTILLGTYNYMGMTFDPD-VIAAGKEALEKFGSGTNGSRMLNGTFHDHMEVEQA 118 
HsLCB1      -VVNGKECINFASFNFLGLLDNPR-VKAAALASLKKYGVGTCGPRGFYGTFDVHLDLEDR 151 
HsLCB2      --NIIKGVINMGSYNYLGFARNTGSCQEAAAKVLEEYGAGVCSTRQEIGNLDKHEELEEL 222 
HsLCB3      --RVIKDVINMGSYNFLGLAAKYDESMRTIKDVLEVYGTGVASTRHEMGTLDKHKELEDL 214 
ScLCB1      LQEKYTNVFNLASNNFLQLSATEP-VKEVVKTTIKNYGVGACGPAGFYGNQDVHYTLEYD 198 
ScLCB2      --AVY-PCMNLSSYNYLGFAQSKGQCTDAALESVDKYSIQSGGPRAQIGTTDLHIKAEKL 209 
TgSPT1      VICEGVRAYPMSSYSYLDFVREPL-VQEAALAAGRTWSTGNHGARMLGGNMRILRDLEKM 252 
TgSPT2      ITCEGKRAYHMSSYSYLDFMREPL-VQEAALAAGRMWSTGNHGARMLGGNPTVIRELEQI 252 
                      :.: .:: :         .       :.    .     *.       *   
SpSPT       LRDFYGTTGAIVFSTGYMANLGIISTLAGKGEYVILDADSHASIYDGCQQGNAEIVRFRH 178 
HsLCB1      LAKFMKTEEAIIYSYGFATIASAIPAYSKRGDIVFVDRAACFAIQKGLQASRSDIKLFKH 211 
HsLCB2      VARFLGVEAAMAYGMGFATNSMNIPALVGKGCLILSDELNHASLVLGARLSGATIRIFKH 282 
HsLCB3      VAKFLNVEAAMVFGMGFATNSMNIPALVGKGCLILSDELNHTSLVLGARLSGATIRIFKH 274 
ScLCB1      LAQFFGTQGSVLYGQDFCAAPSVLPAFTKRGDVIVADDQVSLPVQNALQLSRSTVYYFNH 258 
ScLCB2      VARFIGKEDALVFSMGYGTNANLFNAFLDKKCLVISDELNHTSIRTGVRLSGAAVRTFKH 269 
TgSPT1      VGRFFGREDSLLCATGFLATMSSICAVAKEGDLIVGDNRLHASLRSGMKLSGAKEMLFRH 312 
TgSPT2      IGRFFGREDALLCATGFLAAMSSICAVAKKGDLIIGDNRLHTSLRVGMKLSGAKEVLFRH 312 
            :  *     ::  . .: :    : :   .   :. *      :  . : . :    *.* 
 
SpSPT       NSVEDLDKRLGRL-----PK-----EPAKLVVLEGVYSMLGDIAPLKEMVAVAKKHGAMV 228 
HsLCB1      NDMADLERLLKEQEIEDQKNPRKARVTRRFIVVEGLYMNTGTICPLPELVKLKYKYKARI 271 




HsLCB2      NNMQSLEKLLKDAIVYGQPRTRR-PWKKILILVEGIYSMEGSIVRLPEVIALKKKYKAYL 341 
HsLCB3      NNTQSLEKLLRDAVIYGQPRTRR-AWKKILILVEGVYSMEGSIVHLPQIIALKKKYKAYL 333 
ScLCB1      NDMNSLECLLNELTE-QEKLEKLPAIPRKFIVTEGIFHNSGDLAPLPELTKLKNKYKFRL 317 
ScLCB2      GDMVGLEKLIREQIVLGQPKTNR-PWKKILICAEGLFSMEGTLCNLPKLVELKKKYKCYL 328 
TgSPT1      NNWHHLQQTLAK--------HRR-KYKNCWIVIESVYSMDGDIADLPVVRRLADQYNCRI 363 
TgSPT2      NNWQHLTQILGS--------MRR-KYIDCWIVIESVYSMDGDIADLPTVRRLADQYKCQI 363 




SpSPT       LVDEAHSMGFFGPNGRGVYEAQGLEG--QIDFVVGTFSKSVGTVGGFVVSNHPKFEAVRL 286 
HsLCB1      FLEESLSFGVLGEHGRGVTEHYGINI-DDIDLISANMENALASIGGFCCGRSFVIDHQRL 330 
HsLCB2      YLDEAHSIGALGPTGRGVVEYFGLDP-EDVDVMMGTFTKSFGASGGYIGGKKELIDYLRT 400 
HsLCB3      YIDEAHSIGAVGPTGRGVTEFFGLDP-HEVDVLMGTFTKSFGASGGYIAGRKDLVDYLRV 392 
ScLCB1      FVDETFSIGVLGATGRGLSEHFNMDRATAIDITVGSMATALGSTGGFVLGDSVMCLHQRI 377 
ScLCB2      FIDEAHSIGAMGPTGRGVCEIFGVDP-KDVDILMGTFTKSFGAAGGYIAADQWIIDRLRL 387 
TgSPT1      LLDEAHGLGVLGKTGRGLEEHFNMPG--AADVIVGTFSKSIGGVGGYITGDNDLVEFLDF 421 
TgSPT2      IVDEAHGLGVLGKSGRGLEEHFNMPG--AADIIVGTFSKSIGGVGGFITCGKDLIEFLEY 421 
             ::*: .:* .*  ***: *  .:      *.  ..: .:..  **:              
SpSPT       ACRPYIFTASLPPSVVATATTSIRKLMTA------HEKRERLWSNARALHGGLKA----- 335 
HsLCB1      SGQGYCFSASLPPLLAAAAIEALNIMEEN------PGIFAVLKEKCGQIHKALQGISGL- 383 
HsLCB2      HSHSAVYATSLSPPVVEQIITSMKCIMGQDGTSLGKECVQQLAENTRYFRRRLKE----- 455 
HsLCB3      HSHSAVYASSMSPPIAEQIIRSLKLIMGLDGTTQGLQRVQQLAKNTRYFRQRLQE----- 447 
ScLCB1      GSNAYCFSACLPAYTVTSVSKVLKLMDSN------NDAVQTLQKLSKSLHDSFASDDSL- 430 
ScLCB2      DLTTVSYSESMPAPVLAQTISSLQTISGEICPGQGTERLQRIAFNSRYLRLALQR----- 442 
TgSPT1      HAPGSVFSAPLTAYSAGGAMMAFELMQGE-----QSWRIAKAQENAKYLRHALQTGLGLW 476 
TgSPT2      HALGSVFSAPLTAYSAGGAKKAFELMQGE-----HRWRIAKAQENAIYLRRALKTGNGNW 476 
                  ::  :           :. :                      ::  :        
SpSPT       -------MGFRLGTETCDSAIVAVM---LEDQEQAA------------------------ 361 
HsLCB1      ----------K----VVGESLSPAFHLQLEESTGSRE----------------------- 406 
HsLCB2      -------MGFIIYGN-EDSPVVPLM---LYMPAKIG------------------------ 480 
HsLCB3      -------MGFIIYGN-ENASVVPLL---LYMPGKVA------------------------ 472 
ScLCB1      ----------RSYVIVTSSPVSAVLHLQLTPAYRSRKFGYTCEQLFETMSALQKKSQTNK 480 
ScLCB2      -------LGFIVYGV-ADSPVIPLL---LYCPSKMP------------------------ 467 
TgSPT1      PKDYPAERKFELEGVACTTVIPVVF---PHDGDRVF------------------------ 509 
TgSPT2      PPDYPADKKYEVEGIECTTVIPVVF---PNDPYRLC------------------------ 509 
                                :   :                                    
SpSPT       ---------MMW-----QALLDGGLYVNMARP-------PATPAGTFLLRCSICAEHTPA 400 
HsLCB1      ------QDVRLLQEIVDQCMNR-SIALTRARYLEKEEKCLPPPRGRTGESCVHHQGGSPG 459 
HsLCB2      ---------AFG-----REMLKRNIGVVVVGF-------PATPIIESRARFCLSAAHTKE 519 
HsLCB3      ---------AFA-----RHMLEKKIGVVVVGF-------PATPLAEARARFCVSAAHTRE 511 
ScLCB1      FIEPYEEEEKFLQSIVDHALINYNVLITRNTIVLKQET-LPIVP--SLKICCNAA-MSPE 536 
ScLCB2      ---------AFS-----RMMLQRRIAVVVVAY-------PATPLIESRVRFCMSASLTKE 506 
TgSPT1      ---------RVT-----QAMLKRGWMVAAAAY-------PACPLNRPRIRVTATAAYNQK 548 
TgSPT2      ---------CVT-----RALFSKGWVVGAAMY-------PACPLMRPRIRITATAAYTKE 548 
                      .      : :      :                              .   
 
SpSPT       QIQTVLGMFQAAGRAVGVIG---------------------------------------- 420 
HsLCB1      --RPALGRVPGP---WPPATQ---HAERTQDSRWPWSGLKESKNMWIFDRIVTKWCQYGP 511 
HsLCB2      ILDTALKEIDEVGDLLQLKYSRHRLVPLLD-------RPFDE--------TTYEETED-- 562 
HsLCB3      MLDTVLEALDEMGDLLQLKYSRHKKSARP--------ELYDE--------TSFELED--- 552 
ScLCB1      ELKNACESVKQS---I------------------------------------LACCQESN 557 
ScLCB2      DIDYLLRHVSEVGDKLNLKSNSGKSSYDGKRQRWDIEEVIRR--------TPEDCKDDKY 558 
TgSPT1      MMDEFVKSLVEVTVECPPTDMLR------------------------------------- 571 
TgSPT2      IMDKFVRDLVKTTVDVPLTTEVEDG--------------------------PITL----- 577 
                    .                                                    
SpSPT       --- 420 
HsLCB1      IV- 513 
HsLCB2      --- 562 
HsLCB3      --- 552 
ScLCB1      K-- 558 
ScLCB2      FVN 561 
TgSPT1      --- 571 










The results confirmed that both human SPT1 (HsLCB1) and yeast SPT1 (ScLCB1) are 
lacking the active site residue (lysine) (figure 3-4), and indicated that these subunits 
work in a regulatory role (non-catalytic role). Also, these subunits lack the histidine 
residue (in SpSPT His234) involved in PLP binding. The other alignments have both 
these residues as illustrated in table (3-1). 
Table (3-1) Active site and PLP binding residues within mammalian SPT2 (human 
and yeast) and T. gondii SPT1 and 2. Comparing with the bacterial model (SpSPT) 
























The results suggested that both TgSPT1 and TgSPT2 are catalytically active. In 
addition, the lack of sequence identity to the eukaryotic SPT2 and the similarity to 
the bacterial enzyme (28 and 30% identity, and 47 and 46% similarity, in the C-
terminal region of TgSPT1 and 2 respectively) indicate that the protozoan SPT has a 
prokaryotic origin.  A recent study confirmed this by using a phylogenetic approach 
(Mina et al., 2017) (figure 3-6). 
SPT in organisms Residue site Suggested function 
SpSPT Lys265 SPT active site 
HsLCB2 Lys379 SPT active site 
HsLCB3 Lys371 SPT active site 
ScLCB2 Lys367 SPT active site 
TgSPT1 Lys400 SPT active site 
TgSPT2 Lys400 SPT active site 
SpSPT His234 Involved in PLP binding 
HsLCB2 His347 Involved in PLP binding 
HsLCB3 His339 Involved in PLP binding 
ScLCB2 His334 Involved in PLP binding 
TgSPT1 His369 Involved in PLP binding 
TgSPT2 His369 Involved in PLP binding 




Figure (3-6) Phylogenetic tree produced from a genetic distance matrix showing the 
relationship between the eukaryotic catalytic subunit of serine 
palmitoyltransferase (LCB2) and the prokaryotic and apicomplexan orthologues 
(SPT). The Opistokonta (animals and fungi) are coloured blue; the Excavata 
(subgroup of unicellular eukaryotes) are yellow; Amoebozoa (amoeboid protozoa) 
are grey; Archaeplastida (plants and algae, containing cyanobacterium-derived 
plastid) are green; Rodophyta (a subgroup of the Archaeplastida - red algae) are 
red; Chromalveolata (unicellular eukaryotes containing red algal derived plastid) 
are turquoise; Sphingomonadales (alphaproteobacteria with the ability 






























Using the T. gondii protein sequences in BLAST searches allowed the identification of 
orthologues in other apicomplexan parasites: Eimeria tenella – EtSPT; Plasmodium 
falciparum– PfSPT; and P. vivax – PvSPT (Mina et al, 2017). Along with the bacterial 
S. paucimobilis SPT (SpSpt), as structural data is available (Yard et al., 2007), the 
apicomplexan sequences were aligned using T-Coffee Expresso (Di Tommaso et al., 
2011). The results indicated the presence of an N-terminal extension in the 
apicomplexan SPTs (figure 3-7). Using the Phobius tool, transmembrane domains 
were predicted. The results indicated that the most likely transmembrane domain is 
within this N-terminal extension: TgSPT1 a.a. 27-47 (figure 3-8A); and in TgSPT2 a.a. 
29-47 (figure 3-8B). Both of these lay within the (figure 3-8). Kyte and Doolittle 
hydrophobicity/hydrophilicity predictions supported these results, with the 
transmembrane domains predicted as a.a 27-48 and 29-47 for TgSPT1 and TgSPT2 
respectively (figure 3-9).  
Figure (3-7) Sequence alignment of the predicted serine palmitoyltransferases from 
4 members of the Apicomplexa (Toxoplasma gondii – TgSPT1 and 2; Eimeria tenella 
– EtSPT; Plasmodium falciparum – PfSPT; and P. vivax – PvSPT) and the 
characterised enzyme from the prokaryote Sphingomonas paucimobilis (SpSPT). 
Conserved residues (including those in the active site) identified by analyses of the 
SpSPT structure and homology modelling of the human functional orthologue 
(LCB2), are highlighted in red, with white text denoting similarity.  Blue boxes 
denote conserved domains. The canonical lysine demonstrated to form an internal 
aldimine with the co-factor PLP at SpSPT position 265 is highlighted. The N-terminal 
extensions unique to the predicted apicomplexan enzymes harbour a 
transmembrane domain predicted by Phobius (Käll and Sonnhammer 2004), (TMD, 
bold underlined). The figure was produced using ESPript 3.0 (Gouet and Courcelle, 
2003). 
  









Figure (3-8) Transmembrane prediction for A. TgSPT1 and B. TgSPT2 by using 
Phobius tool (http://www.ebi.ac.uk/Tools/pfa/phobius/) 




Figure (3-9) the hydrophobicity of Kyte and Doolittle parameter to predict the 
hydrophobicity/hydrophilicity of A. TgSPT1 and B. TgSPT2    
 
A.                                                                B. 
 
The predicted transmembrane domain in the apicomplexan SPTs indicated that, like 
the eukaryotic SPT, they are associated with the membranes (Han et al., 2004). The 
prokaryote SPT lack this domain and are cytoplasmic (Yard et al., 2007).  It has now 
been confirmed that TgSPT1 is ER localized (Mina et al., 2017).  Also, these data 
demonstrate that aside from T. gondii the Apicomplexa encode a single SPT, 










Chapter four:  























This chapter examines the function and role of TgSPT2 in the T. gondii de novo 
sphingolipid biosynthestic pathway through the analyses of biochemical activity and 
subcellular localization TgSPT2, and the deletion of both TgSPT1 and 2 by 
homologous recombination. 
 
4.2 Toxoplasma gondii serine palmitoyltransferase 2 (TgSPT2) expression 
and purification 
Recombinant TgSPT2 was expressed in E. coli from the plasmid 
pOPIN_HIS_SUMO_C3_∆158TgSPT2 (GeneScript) as described in materials and 
methods (Chapter 2). The fusion protein produced was TgSPT2, lacking the first 158 
a.a. (∆158 TgSPT2), N-terminally tagged with a histidine-tag which was used in the 
purification process and the Small Ubiquitin-like Modifier (SUMO) protein was used 
to enhance solubility and stability (Yan et al., 2009). A C3 containing the protease 
cleavage site followed the tags to allow cleavage using HRV 3C protease and 
purification of ∆158 TgSPT2. This truncated protein was used because bioinformatic 
analyses indicated that the first 100 a.a. contains a transmembrane domain (Chapter 
3), and removal of this domain is likely make the purified protein more soluble and 
easier to purify. Notably, previous studies in the Denny lab demonstrated that 
TgSPT1 lacking 158 a.a. (∆158 TgSPT1) was soluble and catalytically activity (Thye, 
2014; Mina et al, 2017).  
∆158 TgSPT2 was purified and cleaved as described (Chapter 2), and the resultant 
protein analyzed using SDS-PAGE. The results showed that the HIS-SUMO-3C-
TgSPT2 was resistant to cleavage by the HRV 3C protease (figure 4-1) for unknown 
reasons, the band migrating at about 60 kDa is the fusion protein composed of ∆158 
TgSPT2 (46.7 kDa) and SUMO with His6x 12.2 (kDa). Further modifications in the 








Figure (4-1) SDS-PAGE showed that the molecular weight of the purified 











4.3 TgSPT2 activity assay 
To establish the activity of TgSPT2, the uncleaved 60kDa fusion protein was studied 
as described (Chapter 2) by adding the substrates serine and palmitoyl-CoA to the 
protein in the presence of co-factor pyridoxal phosphate (PLP). Following 
incubation and separation of the lipid faction, ultra-performance liquid 
chromatography UPLC electron spray ionization (ESI) mass spectrometry (MS) was 
used to measure the formation of 3-KDS. UPLC ESI results showed that the 3-KDS, 
which has the molecular weight (M.W.) of 300.29 KDa, was formed with retention 
time (RT) 3.75 mins. The MS spectrum in figure 4-2 shows 2 peaks: 300.29, the 
accurate mass of 3-KDS; and 282.28, the accurate mass of 3-KDS with the loss of 
water (H2O). This study demonstrated that TgSPT2 is a functional, bacterially-
derived, SPT even as a fusion protein. This is like TgSPT1 (Mina et al, 2017) and 
indicated the important role for both SPT isoforms in the de novo T. gondii 
sphingolipid biosynthetic pathway.  








Figure (4-2) Mass spectrometry of lipids extracted froman  in vitro reaction of 
the TgSPT2 Δ158 fusion with serine and palmitoyl CoA as substrates and PLP 
as co-factor. The peak 300.29 corresponds to the mass of 3-
ketodihydrosphingosine C18H37NO2, 282.28 is the same molecule with the loss 
of water. 
 
4.4 The sub-cellular localization of TgSPT2 
To try and understand whether TgSPT2 functions as a normal ER bound eukaryotic 
SPT (rather than a cytoplasmic bacterial SPT) the subcellular localization of the T. 
gondii enzyme was established. To allow localization yellow fluorescent protein 
(YPF) was C-terminally fused to TgSPT2 in the pG1-TgSPT2_YFP (Chapter 2). This 
plasmid was transfected into isolated tachyzoite T. gondii and these used in infect 
Human Foreskin Fibroblast (HFF) cells. To allow co-localization, plasmids encoding 
markers for the Golgi apparatus [Golgi Reassembly and Stacking Protein (GRASP)] 
tagged with red fluorescent protein (RFP) (Pfluger et al., 2005), and the endoplasmic 
reticulum [green fluorescent protein (GFP)] tagged with the ER retention signal 
HDEL (Boevink et al., 1999) were co-transfected.  
 




4.4.1 TgSPT2 co-localization with the Golgi marker GRASP_RFP 
T. gongii tachyzoites transfected with the constructed pG1TgSPT2_YFP and pTub-
GRASP-RFP as described (Chapter 2). HFF cells infected with these transiently 
transfected tachyzoites were then fixed, stained and imaged using a Zeiss Apotome 
microscope and, for higher resolution, a Zeiss 880 with Airyscan microscope (figure 
4-3A-D). The results from the high-resolution analyses showed that the ectopically 
expressed TgSPT2_YFP (figure 4-3B) is not localized to the Golgi apparatus (Red) 
(figure 4-3C, 4-3D).   
Figure (4-3) Subcellular localisation of TgSPT2 and GRASP imaged using the 
Zeiss LSM 880 microscope with Airyscan with appropriate filters. HFF and 
tachyzoite nuclei stained with 4',6-diamidino-2-phenylindole (DAPI) (Blue, 4-




























4.4.2 TgSPT2 co-localization with the ER marker GFP_HDEL 
The same steps as in 4.4.1 were used in this experiment except that p30-GFP_HDEL 
instead of pTub-GRASP-RFP was transfected with pG1TgSPT2_YFP, and the fixed 
and stained cells subsequently imaged using DeltaVision OMX microscopy. The 
results showed that the TgSPT2 is co-localized with GFP_HDEL (figure 4-4). 
Therefore, this study concluded that TgSPT2 is, like the mammalian orthologue, 
localized to the ER. This resembles the TgSPT1 isoform (Mina et al., 2017), and 
shows that although TgSPT1 and 2 are bacterial in origin, but their function in the 
ER like in other eukaryotes. 
Figure (4-4) DeltaVision OMX imaged 125 nm optical slice of T. gondii within a 
parasitophorous vacuole (PV) of a HFF infected cell. DAPI (Figure4-4A, Blue), 
showing parasite nuclear (Nu) and apicoplast (Ap) DNA; Anti-GFP antibody 
stain (Figure4-4B, Alexa Fluor® 594, Red) of episomally expressed GFP-HDEL, 
showing the parasite ER) TgSPT2-YFP ( Figure4-4C, Green); Merge of Figure4-
4A-C showing overlap of TgSPT2-YFP with the ER marker GFP-HDEL (Figure4-
4D, Yellow). Scale bar shown.  

















4.5 TgSPT2 knockout (KO) 
4.5.1 KO Plasmid (pTub5CatSagF1F2) construction and mapping 
The plasmid used (pTub5CatSag1F1F2, made in collaboration with Dr Hosam Shams-
Eldin and Philip Stahl [University of Marburg]), contained a construct designed to 
knockout the 2 tandem copies of T. gondii SPT (TgSPT1 and TgSPT2) by homologous 
recombination. This construct and the intended knockout process is shown in Figure (4-
5).  















                               Chloramphenicol Marker (CAT)          Marker flank region 


















To confirm the identity of the SPT knockout construct the plasmid was mapped by 
digestion with the restriction enzymes NotI, NotI + XhoI, NotI + HindIII and XhoI. 
 
Figure (4.6) Gel electrophoresis of restriction enzyme digests Figure 4.6A: kb 
ladder; Figure 4.6B: NotI; Figure 4.6C: NotI+XhoI; Figure 4.6D: NotI+HindIII; 














 Single digestion with XhoI (Figure 4.6E) shows a single band and indicated the plasmid 
to be approximately 7.2 kbp in size. NotI digestion gave 2 bands of approximately 6 kbp 
and 1.2 kbp, indicating 2 NotI sites (Figure 4.6B). Double digestions with NotI and XhoI 
(Figure 4.6 C) should give three bands, with 2 NotI sites and a single XhoI site (Figure 4.6B 
and E), however only 2 are evident at approximately 3 kbp and 1.2 kbp. Double digestion 
with NotI and HindIII (Figure 4.6D) gave 3 bands as expected (approximately 4.5 kbp, 1.5 
kbp and 1.2 kbp). Comparing the restriction pattern with the plasmid map (Figure 2.1) it 
is clear that the pattern is the expected one. The 2 rather than 3 bands seen with NotI 
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that the construct could be linearized and used delete the 2 tandem SPT genes in T. 
gondii by homologous recombination and chloramphenicol selection. 
 
4.5.2 TgSPT1 and 2 knockouts 
XhoI linearized plasmid was transfected into T. gondii ∆Ku80-HXG (Rommereim et al., 
2013), The Ku80 protein is responsible for non-homologous recombination, deletion of 
this gene increases the rate of the homologous recombination and maximizes the 
changes of achieving the desired knockout. Under chloramphenicol selection, after 3 
rounds of egress the parasites were collected, purified and. gDNA extracted. By using 
the specific primers as following: 
 
P1: CCCCTCGAGCCCTCCACACGCTGAATTTCG 
P4: CCCGAGCTCTTGATCGCAACTTTCTGTGCAGTA  
P5: CCACCGTTGATATATCCC CAT  
P6: GTAATTCATTAAGCATTCTGC 
 
(P1 and P4) for construct flank regions and the chloramphenicol marker (CAT, P5 and P6) 
the selected parasites were analyzed for the replacement of the TgSPT locus with the 
chloramphenicol (CAT) marker (Figure 4-7). 
The wild type locus is amplified in Figure4-7B (8kb), in a successful knockout this should 
be lost and replaced with the CAT marker giving a smaller product (4.2kb). Therefore, 
there was no evidence that the knockout had been successful Figure4-7C. In further 
experiments various concentrations (20ng, 60 ng and 110 ng) of template T. gondii 
SPTKO-∆Ku80-HX DNA were analyzed for integration of the construct (4.2kb) and the 
presence of the CAT marker (0.6kb), Figure4-7D, F and H and Figure4-7E, G and I 
respectively. The CAT marker was detected in all samples (Figure4-7E, G and I) however 
only the 110ng sample (Figure4-6H) show any evidence of integration of the construct 
(4.2kb, arrow). Even here the band is very faint and the wild type locus (8kb) is dominant, 
these preliminary results suggest that TgSPT1 and 2 are important for T. gondii fitness; 




however future work is needed using for example CRISPR/Cas9 (Sidik et al., 2016) to KO 
either TgSPT1 or TgSPT2 or both. 
 
Figure (4-7) PCR screen for TgSPT1 and 2 deletions. T. gondii ∆Ku80-HX and T. gondii 
SPTKO-∆Ku80-HX. Figure 4-7A: kb Markers; Figure 4-7B: P1 and P4 from parent 
RHdeltaKu80; Figure 4-7C:  P1 and P4 from RHdeltaKu80_SPTKO; Figure 4-7D: P1 and 
P4 from RHdeltaKu80_SPTKO 20ng; Figure 4-7E: P5 and P6 from RHdeltaKu80_SPTKO 
20ng; Figure 4-7F: P1 and P4 from RHdeltaKu80_SPTKO 60ng; Figure 4-7G: P5 and P6 
from RHdeltaKu80_SPTKO 60ng; Figure 4-7H: PCR using P1 and P4 from 













A     B         C                      D          E        F         G        H         













Chapter five:  
Study on the effect of AbA and its 










Chapter Five: Study on the effect of AbA and its analogue Cmpd20 against T. gondii 
 87   
 
5.1 Introduction to Aureobasidin A and its derivative compound 20 
(Cmpd20)  
Aureobasidin A (AbA) (figure 5.1A) is a natural cyclic depsipeptide produced by the 
Auriobasidium pullulans strain BP-1938 (Wuts et al., 2015). AbA is a fungicidal and has 
high activity against several clinically relevant fungi, for example Candida spp. and 
Cryptococcus neoformans. AbA inhibits the growth of most fungi at approximately 50 
nM, and is active against its target, the fungal IPCS (AUR1p, the non-mammalian 
sphingolipid synthase), at sub-nanomolar levels (Zhang et al., 2010). However it showed 
only slight activity against Aspergillus fumigatus which has the ability to clear the 
compound by using an efflux pump (Takesako et al., 1993; Wuts et al., 2015). Attempts 
have been made to modify the structure of AbA to increase its effect against A. fumigatus 
(Wuts et al., 2015) which found the most effective analogue generated was Compound 
20 (Comp20, figure 5.1B) with a minimal inhibitory concentration (MIC) against A. 
fumigatus of 1-2 µg/ml. 
 
Figure (5-1) Chemical structure of AbA (A) and its analogue Compound 20 (B). Adopted 
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In the kinetoplastid protozoa Leishmania major, AbA inhibits promastigote growth with 
an EC50 of 0.6 µM, although the target is not the protozoan IPCS (Denny et al., 2006). At 
10 µg/mL-1 AbA also inhibits the in vitro transformation of the related Trypanosoma cruzi 
trypomastigotes to the amastigote form (Salto et al., 2003), although like Leishmania this 
is not due to IPCS inhibition (Figueiredo et al., 2005). It was proposed that AbA inhibits 
amastigote replication inside the macrophage, and trypomastigote egress, due to 
subversion of host cell nitric acid production and phagocytic capacity (Figueiredo et al., 
2005). Similarly, AbA has been shown to be active against T. gondii tachyzoites by Sonda 
et al (2005), who indication that it inhibited IPC synthesis. 
In this study AbA and its analogue (Cmpd20) (provided by Aureogen Biosciences Inc.) 
were tested to show the effect of both of them on the replication of both tachyzoite and 
bradyzoite T. gondii and parasite de novo sphingolipid biosynthesis.    
 
5.2 The response of host (CHO) sphingolipid biosynthesis pathway to T. 
gondii infection 
To establish the effect of T. gondii infection on mammalian host cell (CHO) sphingolipid 
biosynthesis, the modulation of host SPT (the first and rate-limiting step in sphingolipid 
biosynthesis), and SMS1 and SMS2 were investigated (Romano et al., 2013). Initially 
conventional PCR was used for quality control using primers for LCB2 (subunit 2 of SPT), 
SMS1, SMS2 and β-tubulin (a housekeeping gene). Subsequently, real time PCR or qPCR 
was done to investigate the differences in gene expression for these genes of interest 
(LCB2, SMS1 and SMS2 with respect to β-tubulin) in infected and uninfected CHO cells. 
The results showed that the relative expression of host LCB2, SMS1 and SMS2 were 0.82, 
1.02 and 0.93 respectively (figure 5.2), meaning that they are not significantly affected 
by T. gondii infection. This indicated that manipulation of host sphingolipid biosynthesis 
is not important for parasite proliferation, agreeing with the hypothesis that T. gondii is 
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Figure (5-2) RT-PCR shows expression of host sphingolipid biosynthetic enzymes are 
largely unaffected by Toxoplasma infection (GOI:HKG; n=3). β-tubulin used as 










5-3 The effect of known anti-fungal sphingolipid biosynthesis inhibitors 
aureobasidin A (AbA) and an analogue (Cmpd 20) on Toxoplasma 
proliferation in acute and chronic infection 
 
 
5.3.1 The effect of compounds on T. gondii proliferation in acute infection 
The AbA been shown to inhibit the proliferation of tachyzoite form of T. gondii. The 
effective concentration of AbA reducing proliferation by 50% (ED50) was estimated to be 
0.3 µg/mL-1 by counting the cell number 48h post infection and 46h post AbA addition 
(Sonda et al., 2005). To gain a more robust result, in this study we used the yellow 
fluorescent protein (YFP) labeled Toxoplasma RH-strain (RH-HX-KOYFP2-DHFR 
Toxoplasma, Gubbels et al., 2003). 20h after infecting HFF host cells with these YFP 
expressing T. gondii (as described, Chapter 2), the compounds were added and the cells 
left without washing for 6 days and the fluorescence measured.  Then the data analyzed 
and the ED50 was calculated for AbA (figure 5-3 A) and Cmpd20 (figure 5-3 B). The results 
demonstrated that both compounds showed activity against Toxoplasma gondii 
tachyzoites under these conditions. The ED50 of AbA was 0.75, 95% CI 0.60 to 0.93 µg     
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mL-1, and was more slightly efficacious than its analogue (Cmpd20), ED50 of 1.49, 95% 
CI 1.20-1.85 µg mL-1.    
 
Figure (5-3) ED50 of AbA (A) and Cmpd20 (B) µg mL-1; (95% CI [Confidence Interval]) 
against the RH-HX-KOYFP2-DHFR T. gondii tachyzoites in HFF cells. 6 days post addition 
of the compounds. In agreement with Sonda et al. (2005), both compounds were not 
toxic to HFF cells under the experimental conditions. Calculated by using GraphPad 









Sonda et al. (2005) indicated by using indirect assay (vacuole formation), that the efficacy 
of AbA against T. gondii is partially reversible after 24 h and irreversible after 48 h. For 
further analyses of the reversibility of the efficacy of both AbA and Cmpd20, the infected 
HFF cells were washed after 2 and 8 h after compound addition, then incubated for 6 
days before fluorescence plates readings were taken. The results showed that AbA T. 
gondii efficacy was partially reversible after 2 h (ED50 of 9.58, 95% CI 6.66 to 13.76 µg mL 
µg mL-1; figure 5-4A), and 8 h exposure (ED50 of 4.82, 95% CI 3.73 to 6.22 µg mL-1; figure 
5-4C). However, Cmpd20 activity was demonstrated to be almost completely reversible 
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Figure (5-4) ED50 of AbA (A) and Cmpd20 (B) µg mL-1 wash out 2 h post compound 
(95% Confidence Interval), and AbA (C) and Cmpd20 (D) washout 8 h post compound 
(95% Confidence Interval). RH-HX-KOYFP2-DHFR T. gondii in HFF cells. Calculated by 
using GraphPad Prism 7, log (inhibitor) vs normalized response- variable slope> 10 µg 












Two hypotheses may explain the efficacy of AbA and Cmpd20 against the parasites, first 
they may target sphingolipid biosynthesis as in the fungi; second the ability of the host 
cell to clear infection may be affected (Figueiredo et al., 2005). In order to investigate 
the second hypothesis T. gondii tachyzoites isolated from the infected host cells as 
described (Chapter 2) were treated with various concentrations of AbA or Cmpd20 for 2 
or 8 h and, after washing, used to infect HFF host cells for 6 days. The results showed 
that the efficacy of AbA after 2 h treatment (ED50 of 4.78, 95% CI 3.95 to 5.79 µg mL-1) 
was greater than Cmpd 20 (figure 5-5). The longer period post-isolation (8 h) lead to 
untreated tachyzoites losing infectivity. These results indicated that both AbA and 
Cmpd20 have a direct effect on the parasite, AbA showing greater efficacy as above. This 
indicates that host modulation may not be a major factor in efficacy, however, in order 
to know are whether these compounds target parasite sphingolipid biosynthesis more 
analyses was needed.  
A B 
C D 
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Figure (5-5) Figure (5-5) ED50 of AbA (A) and Cmpd20 (B) µg mL-1 2 h exposure to isolated 
RH-HX-KOYFP2-DHFR T. gondii tachyzoites (95% Confidence Interval). Calculated by 
using GraphPad Prism 7, log (inhibitor) vs normalized response- variable slope. > 10 µg 
mL-1 – ED50 could not be determined. Representative in triplicate dataset. 
Further analyses were performed to show the effects of both compounds on the T. gondii 
de novo sphingolipid biosynthesis pathway. This study suggested in agreement with 
(Pratt et al., 2013; Romano et al., 2013) that the host sphingolipid biosynthesis is 
unaffected and non-essential for T. gondii proliferation, so T. gondii de novo sphingolipid 
biosynthesis may be regarded as an attractive drug target for antiprotozoals. Whilst 
some published studies reported that AbA inhibited a Toxoplasma IPCS (Sonda et al., 
2005 and Coppens et al., 2013),  another demonstrated that IPCS activity encoded by the 
T. gondii enzyme TgSLS, was not sensitive to this compound (Pratt et al., 2013). To 
analyze both AbA and Cmpd20 an auxotrophic TgSLS complemented yeast strain 
(YPH499-HIS-GAL-AUR1 pRS426 TgSLS with YPH499-HIS-GAL-AUR1 pRS426 AUR1 as a 
control) were used and their sensitivity to the compounds were tested at two 
concentrations (5 and 10 µg mL-1). The results showed that the Toxoplasma enzyme 
(TgSLS) conferred the resistance to yeast against both compounds when compared with 
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Figure (5-6) Yeast dependent on the expression of the Toxoplasma AUR1p orthologue 
TgSLS (YPH499-HIS-GAL-AUR1 pRS426 TgSLS) are resistant to Aureobasidin A (AbA) and 
Compound 20 (Cmpd 20) at 5 and 10 μg mL−1. This contrasts to the sensitivity of yeast 
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In addition to TgSLS function as an IPCS in yeast and in vitro, Toxoplasma have also been 
demonstrated by using the incorporation of tritiated serine, to produce the 
sphingomyelin (SM) and glycosphingolipids (GSLs) like mammalian cells (Gerold and 
Schwarz, 2001). Many studies confirmed that the isolated Toxoplasma have SM, GSLs 
and high levels of ethanolamine phosphorylceramide (EPC) which found in low levels in 
mammalian cells (Welti et al., 2007 ; Pratt et al., 2013). To study the effects of AbA and 
Cmpd20 on total sphingolipid biosynthesis in T. gondii, parasites were metabolically 
labeled in the presence of the compounds as described (Chapter 2). Firstly, an 
experiment demonstrating total sphingolipid biosynthesis in purified T. gondii 
tachyzoites compared with that in host cells (vero cells) and Saccharomyces cerevisiae 
was performed.  T. gondii tachyzoites were shown to synthesize a complex of 
sphingolipids including SM and EPC (co-migrating with mammalian equivalents (Vacaru 
et al., 2013). IPC, clearly shown in yeast, was not detected in this experiment and 2 other 
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Figure (5-7) Vero cells (Host), isolated T. gondii tachyzoites (Toxo) and Saccharomyces 
cerevisiae (Yeast), labeled for 1 h with NBD-C6-ceramide and complex sphingolipids 
then fractionated by HPTLC. Like the host cells, the parasites synthesize sphingomyelin 
(SM) and ethanolamine phosphorylceramide (EPC), two unique sphingolipids are also 
produced (X and Y). However, unlike in S. cerevisiae, no labelled inositol 












After analyzing the total sphingolipid in T. gondii, host and yeast, further analyses were 
needed to establish the effects of AbA and Cmpd20 on the T. gondii sphingolipid 
biosynthetic pathway. Isolated T. gondii tachyzoites were treated with AbA and Cmpd20 
at 10 µg mL-1 for 1,4 and 7 h, before labeling with NBD-C6 ceramide for 1 h then. The 
results showed that the compounds had no effect on the synthesis of the sphingolipids 
in T. gondii when it compared with controls (figure 5-8). This demonstrated that neither 
compounds effected this pathway, and there may be another target in this parasite. 
However, it was clearly shown that the profile of complex sphingolipid had some changes 
at the times 4 and 7 h, the X and Y levels were increased at these points of times, SM 
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levels unchanged and EPC levels were decreased (figure 5-8). These results are indicated 
that the absence of host cells lead to the modification of sphingolipids or catabolism in 
T. gondii. More study, particularly metabolomic analyses of purified treated T. gondii with 
both compounds, is needed to establish the mode of action of AbA and Cmpd20 action 
against T. gondii.   
Figure (5-8) Isolated Toxoplasma tachyzoites treated with Aureobasidin A (AbA) and 
Compound 20 (Cmpd 20) at 10 μg mL−1 for 1 (A), 4 (B) and 7 (C) hours before labelling 
with NBD-C6-ceramide for 1 h. Neither compound affected the complex sphingolipid 
profile synthesized at any time point when compared with the vehicle control (DMSO). 
SM – Sphingomyelin (SM); EPC – Ethanolamine PhosphorylCeramide; X and Y – 










5.3.2 The compounds effects on T. gondii proliferation in chronic infection 
The chronic infection of T. gondii is caused by the encysted bradyzoite stage. New 
therapies or drugs urgently needed against this type of infection (Antczak et al., 2016). 
Therefore, AbA and Cmpd20 were testing against bradyzoite stage parasites.  
Type II Pru strain of T. gondii modified to express GFP (Kim et al., 2007) was used in this 
study. Following a pH shift to stimulate the transformation of tachyzoite into bradyzoite 
forms (Soete et al., 1994), infected HFF cells were treated with the compounds for 3 
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days. The results showed promising activity against this stage (figure 5-9), again the 
efficacy of AbA (ED50 of 2.15, 95% CI 1.96 to 3.23 µg mL-1) was higher than Cmpd20 (ED50 
of 3.74, 95% CI 3.13 to 4.47 10 µg mL-1). Therefore, AbA and its analogue represent 
promising candidates for the development of therapies to treat both acute and chronic 
toxoplasmosis.      
Figure (5-9) ED50 of Aureobasidin A (A, AbA) or Compound 20 (B, Cmpd20) μg mL−1 (95% 
Confidence Interval) – against the T. gondii Pru bradyzoites in Human Foreskin 
Fibroblast (HFF) cells. Three days post addition of the compounds. Calculated using 
GraphPad Prism 7, log (inhibitor) vs normalized response – Variable slope. 
Representative in triplicate dataset. 
These results agreed with the others who proposed that the effect of AbA on the 
kinetoplastid parasites Leishmania spp. and T. cruzi is not due to the inhibition of IPCS 
(Figueiredo et al., 2005; Denny et al., 2006; Sevova et al., 2010). These results also agree 
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Metabolomics is an emerging technology widely used now to detect low molecular 
weight (<1400 Da) molecules (Vincent and Barrett, 2015) and is called the metabolome 
in a biological sample (Besteiro et al., 2010; Paget et al., 2013). These low molecular 
weight molecules or metabolites (for example sugars, amino acids and fatty acids; 
Willger et al., 2009), are different in their chemical characteristics (molecular weight, 
solubility etc) and physical characteristics (volatility etc; Dunn and Ellis, 2005), and are 
essential for an organism’s survival. In pathogens that have numerous life cycle stages, 
differences in these metabolites are important in stage differentiation. In addition, we 
can now investigate the response of a pathogen to drug treatment by monitoring 
changes in the metabolome before and after treatment (Besteiro et al., 2010; Berg et al., 
2013). Furthermore, metabolomic analyses are fundamental in the study of the effects 
of genetic modification (Villas-Bôasand and Lane, 2005).     
The benefits behind the metabolomic study of pathogens, including the medically 
important protozoan parasites, are: 
i. The identification of novel parasitic metabolites which can then be used to 
define new drug targets. In addition, the modification of metabolic pathways 
resulting from treatment with a specific drug can be followed (Besteiro et al., 
2010). 
ii. Membranes consist of fatty acids and phospholipids in a certain proportion, 
however under stress, such drug treatment or infection, this proportion may 
be changed (de Azevedo et al., 2014). These changes can be used as 
biomarkers to study the virulence of Leishmania spp. or its resistance to 
treatments for leishmaniasis (Messaoud et al., 2017). Metabolomic analyses 
have been used to accurately detect changes in sarcosine and fatty acid 
biomarkers for prostate (Sreekumar et al., 2009) and colorectal (Ritchie et al., 
2010) cancer respectively. 
iii. Metabolomics can be used to analyse cellular enzymatic reactions that are 
controlled by many factors, for instance metabolite concentrations, signaling 
molecules and post-translation alterations (Saito et al., 2010).  




iv. Metabolite differences between the host and an infectious pathogen can be 
exploited to specifically target unique pathogen enzymes (Agüero et al., 
2008). Therefore, metabolomic analyses will help to open the door to develop 
more specific new drugs (Kafsack and Llinás, 2010).  
 
In this study, we used Leishmania major as a model to study the role of IPC synthase in 
the protozoa by exploiting the availability of two specific inhibitors identified in-house, 
clemastine [known as anti-histamine (Riviere and Papich, 2013)] (Brown et al, submitted) 
and a benzazepine (compound 35 [CMPD35] identified in a high throughput screen of 
the GSK compound library, Norcliffe et al, submitted). The effect of these two 
compounds on the metabolome was analysed and, in parallel, a lipidomic study was 
performed to study the perturbation of IPC synthesis.  
Leishmania spp. are the causative agents of leishmaniasis and are one of the protozoan 
parasites that cause serious human disease, alongside the related kinetoplasts 
Trypansoma cruzi (Chagas disease) and T. brucei (African sleeping sickness) (Kafsack and 
Llinás, 2010). There is an urgent need to either further develop the currently used drugs, 
due to their limitations resulting from toxicity, cost and route of administration; or to 
find new drugs that are specifically targets against the parasite, for example enzymes 
that modulate metabolism.  
Leishmania spp. membrane lipids, and the biosynthetic enzymes that produce them, may 
be good drug targets due to the significant differences in the composition and function 
when compared with mammals (Zhang and Beverley, 2010). Phospholipids are regarded 
as one of the main lipid components of biological membranes, and consist of 
glycerophospholipid and sphingolipids. Glycerophospholipids compromise a hydrophilic 
head group linked to fatty alcohol chains by a phosphate group. Sphingolipids consist of 
a hydrophilic head group linked to a ceramide via phosphate (Ramakrishnan et al., 2013).   
This study adds to the field by analysing metabolite perturbation with a focus on the 
sphingolipid biosynthetic pathway, which contains protozoan unique features (Mina and 
Denny, 2017).  




The life cycle in Leishmania spp. is divided into two stages, promastigote in the sand-fly 
vector and amastigote within the mammalian host macrophages (Ramakrishnan et al., 
2013).  
Leishmania amastigotes are not suitable for metabolomic studies for several reasons: 
a. The difficulty of separation from the host and the inability to define if a 
metabolite belongs to the host or parasite (Decuypere et al., 2008; Vincent et al., 
2014). 
b. When isolated, amastigotes transform quickly to promastigote forms (Decuypere 
et al., 2008). 
These concerns can be partly overcome by the use by axenic amastigote forms, where 
the host cells are absent (Peña et al., 2015). However, this system is not established for 
L. major, therefore the promastigote stage was used as it is easy to grow in vitro, this 
avoiding host cell metabolites (Decuypere et al., 2008). 
The two IPC synthase inhibitors used in this study, clemastine and the benzazepine 
(CMPD35), have been shown to have micromolar ED50 and IC50 against L. major parasites 
and IPC synthase. Furthermore, they are also both 10-30 fold less active against a 
sphingolipid-free mutant (Brown et al, submitted; Norcliffe et al, submitted). The mutant 
L. major, ∆LCB2, lacks the sphingolipid biosynthesis pathway because it lacks the first, 
rate limiting enzyme in sphingolipid biosynthesis (SPT) (Denny et al, 2004).   
 
6.2 Effect of clemastine and benzazepine (CMPD35) on the Leishmania 
major FV1 metabolome 
6.2.1 Results of half-time to cell death assay 
This experiment was designed to select the best concentration for the metabolomic 
study. Two final concentrations for clemastine (10 µM and 5 µM) and for the 
benzazepine (80µM and 40 µM) were tested in this study. 
Compound concentrations and the L. major promastigotes were prepared in 24-well 
plates, and incubated at 26°C for 20, 24 and 42 hours. The morphology and number of 
parasites were examined in each of these periods. Clemastine at 10µM for 20 hours lead 




to approximately 50% of the promastigotes being rounded as apposed to spindle shaped. 
This increased to about 95% after 24 hours treatment. At the 5 µM, the effects are 
noticeably less. There was no significant increase in overall parasite number at all 
compound concentrations and time periods (Table 6.1).  
 
Table (6-1) Clemastine treated Leishmania major 
Compound  Clemastine 
Conc. (µM) 10  5  
Time (h) 20 24 20 24 
% rounded 
morphology 
~50%  ~95%  ~40%  ~90%  
No. parasites 
(p.ml-1) 
4.5x106 4.3x106 4.7x106 4.2x106 
 
The benzazepine (CMPD35) at 80 µM, 20 and 24 hours, was toxic to the parasites, 
approximately 30% killed at 20 hours and 40% at 24 hours. The rest were rounded but 
alive as determined by phase microscopy. At the 40 µM and 20 hours, 50% were rounded 
shape and less than 5% dead. This increased to about 10% after 24 hours treatment. 
With respect to the number of parasites, it was demonstrated to be dramatically 
decreased when compared with the clemastine treated promastigotes: for benzazepine 
(CMPD35) at 80 µM for 20 and 24 hours 2.9 x106 p.ml-1 and 3.0 x106 p.ml-1 respectively); 
and at 40 µM, 3.3 x106 p.ml-1 and 3.5 x106 p.ml-1 respectively (Table 6.2). However, no 
change in the shape of untreated parasites at this time of periods, also not count at this 










Table (6-2) CMPD35 treated Leishmania major 
Compound  Benzazepine (CMPD35) 
Conc. (µM) 80  40  
Time (h) 20 24 20 24 
% rounded 
morphology 
~50%  ~50%  >50%  >50%   
% dead ~30% ~40% ~5% ~10% 
No. parasites 
(p.ml-1) 
2.9x106 3.0x106 3.3x106 3.5x106 
 
By increasing the treatment period to 42 hours for both compounds (clemastine and 
benzazepine [CMPD35]) it was demonstrated that the treated parasites were all of the 
rounded morphology but maintained viability. Given the toxicity at the higher 
concentration of benzazepine (CMPD35) seen above (Table 6.2). 
Table (6-3) 42-hour clemastine and CMPD35 treatment of Leishmania major. Selected 
conditions in yellow 
Compound  Clemastine CMPD35 
Conc. 0 10 5 0 80 40 
No. parasites 
(p.ml-1) 
30x106 6.2x106 7.8 x106 29x106 5.8x106 6.1x106 
 
the treatment conditions selected for metabolomic analyses were 10 µM of clemastine 
and 40 µM of benzazepine (CMPD35) for 42 hours (Table 6.3, yellow). This maximized 
compound concentration and treatment periods without compromising cell viability. 
 
 




6.3 Metabolomic analyses of clemastine and benzazepine (CMPD35) 
treated Leishmania major 
As mentioned above these compounds are recognized as specific IPCS inhibitors in L. 
major. Therefore, to investigate the global consequences of IPCS inhibition in this 
protozoan parasite metabolomic analyses were undertaken using the conditions 
outlined above.  Analyses initially focused on L. major sphingolipid synthesis                          
(Figure 6-1).  
Following 42 hours compound treatment, metabolites were extracted and analyzed 
using LC-MS, and the data analyzed by using an Excel interface tool (IDEOM). IDEOM is a 
practical data analysis tool building on developed processing tools, e.g.  mzMatch (a tool 
used for peak and annotation) and XCMS (to extract raw LC-MS data). IDEOM 
automatically clarifies and detects the metabolite peaks with particular consideration for 
the common noise and the positive and negative results obtained by LC-MS platforms 



















Figure (6-1) Sphingolipid biosynthesis pathway in L. major (adopted and modified from 
Zhang et al., 2010). 3 KDS: 3 ketodihydrosphingosine; PI: phosphatidylinositol; PC: 
Phosphatidylcholine; PE: Phosphatidylethanolamine; IPC: Inositol 
phosphorylceramide; IPCS: Inositol phosphorylceramide synthase; EPC: Ethanolamine 
phosphorylceramide, EPCS: Ethanolamine phosphorylceramide synthase; EtN-P: 
ethanolamine phosphate.                                                                                                                                                                                
 
6.3.1 SL metabolite flux in Leishmania major promastigotes treated with 
clemastine 
Using the IDEOM platform for analyses it was found that although there is a significant 
decrease in 3-ketodihydrosphingosine (3-KDS) production ([SP] 3-dehydrosphinganine; 
0.47; P<0.05), there was a significant increase in most of the sphingolipid species 
particularly: dihydroceramide [SP (16:0)] N-(hexadecanoyl)-sphinganine; 39.65-fold; 
P<0.05) and ceramide [SP-hydroxy(16:0)] N-(hexadecanoyl)-4S-hydroxysphinganine; 
8.37-fold; P<0.05). These increased are expected of an IPCS inhibitor, where in the 
absence of enzyme function there would be an increase in substrate concentration, e.g. 
ceramide. Other lipids connected with the pathway also change: phosphatidylinositol is 
increased (PI e.g  O16:0/20:2 (11Z, 14Z); 13.14-fold; P<0.05). Again this was expected as 
it is the other substrate of IPCS synthase. Phosphatidylcholine (PC) is also increased (e.g. 
(18:1/P18:0) -1-(1Z - octadecenyl) -2- (9z- octadecenoyl) -Sn- glycerol-3- phosphocholine; 
5.02-fold; P< 0.05), the PC (unsaturated fatty acid) significantly increase leads to increase 




the membrane fluidity, and that cause the perturbation in the plasma membrane  
function (Alberts et al., 2002;Dowhan et al., 2002).In contrast levels of 
phosphatidylethanolamine (PE 34:0, 0.40-fold, P<0.05) decreased, given the role of 
serine palmitoyltransferase in PE synthesis (Table 6.1) this fitted with the observed 
decrease in 3-KDS. Table 6.1 shows the metabolites of interest that are changed in L. 
major when the parasites are treated with clemastine. Figure 6.2 illustrates all the 
perturbations that occurred within the SL biosynthesis pathway when the parasites were 
treated with clemastine, data which fits the hypothesis the compound is a specific IPCS 




6.3.2 SL metabolite flux in Leishmania major promastigotes treated with 
benzazepine (CMPD35) 
Unlike with clemastine there were no statistically significant changes in 3-KDS (0.75-
fold), dihydroceramide (0.87) or ceramide (1.79). The lack of ceramide build up with 
unexpected with an IPCS inhibitor. However, PI was increased (e.g PI(O-
16:0/20:2(11Z,14Z)); 4.55-fold; P<0.05). Like with clemastine, PC was also increased (e.g. 
PC(15:0/P-18:0); 1.52-fold) and PE was significant decreased (PE 34:0, 0.54-fold P<0.05). 
Sphingomyelin not detected. These data provide limited support for mode of action of 
CMPD35 as an inhibitor of IPCS, i.e. no increase in ceramide. However, labeling 
experiments have clearly demonstrated a reduction in IPC synthesis on treatment 
(Norcliffe et al, submitted).  
Interestingly, the metabolomics results also showed that Leishmania treated with 
clemastine has statistically significant decrease in ergosterol while Leishmania treated 
with CMPD35 has statistically significant increases in ergosterol ([ST(3:0)]ergosta-
5,7,22E-trien-3beta-ol; (0.54 and 2.01-fold respectively). Ergosterol is a sterol found in 
cell membranes of fungi and protozoa (Thomas, and Waters, 2016), and given the 
relationship between sphingolipids and sterols this may be significant. Table 6.1 shows 
the metabolites of interest that are changed in L. major when the parasites are treated 




with benzazepine (CMPD35). Figure 6.3 illustrates the perturbation that occurred within 
the SL biosynthesis pathway in L. major on treatment.  
Table (6-4) Metabolites that are changed when Leishmania major are treated with 
clemastine (Cle) or benzazepine (CMPD35). The predicted formula, mass, pathway 
and confidence levels are shown  
 
Each ‘metabolite’ is assigned a confidence level from 0 to 10 based on an authentic standard compound 
(10 = most confident); Red* indicates metabolites that are significantly changed; SL: sphingolipid; ND: 
not detected. 













10 2.59 1.25 1.0 
3-KDS  C18H37NO2 299.28 
Sphingoid 
bases 
6 0.47* 0.78 1.0 
Dihydrosphinganine ND ND ND ND ND ND ND 
Dihydroceramide C34H69NO3 539.53 Ceramides 5 39.65* 0.78 1.0 
Phytoceramide C34H67NO4 555.52 Ceramides 5 8.37* 1.79 1.0 
Sphingosine C18H39NO2 301.3 SL metabolism 6 1.96 2.22 1.0 
Sphingosine-1-P C18H38NO5P 379.25 
Sphingoid 
bases 
6 0.78 0.76 1.0 




8 0.55 2.05 1.0 







7 0.40* 0.54* 1.0 
Phosphatidylserine C44H80NO10P 813.55 
Glycerophosph
oserines 
5 0.59* 0.46* 1.0 
Phosphatidylcholine C44H86NO7P 771.61 
Glycerophosph
ocholine 
5 5.02* 1.52 1.0 
Phosphatidylinositol C45H85O12P 848.58 
Glycerophosph
oinositol 
8 13.14* 4.55* 1.0 
Ergosterol C28H44O 369.34 Sterols 5 0.54* 2.01* 1.0 




Figure (6-2) Metabolites that are changed in sphingolipid biosynthesis pathway when 
L. major are treated with clemastine (Cle) (adopted and modified from Zhang et al., 
2010). 3 KDS: 3 ketosphinganine; PI: phosphatidylinositol; PC: Phosphatidylcholine; PE: 
Phosphatidylethanolamine; IPC: Inositol phosphorylceramide; IPCS: Inositol 
phosphorylceramide synthase; EPC: Ethanolamine phosphorylceramide, EPCS: 
Ethanolamine phosphorylceramide synthase; EtN-P: ethanolamine phosphate. 
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Figure (6-3) Metabolites that are changed in sphingolipid biosynthesis pathway when 
L. major are treated with benzazepine (CMPD35) (adopted and modified from Zhang 
et al., 2010). 3 KDS: 3 ketosphinganine; PI: phosphatidylinositol; PC: 
Phosphatidylcholine; PE: Phosphatidylethanolamine; IPC: Inositol 
phosphorylceramide; IPCS: Inositol phosphorylceramide synthase; EPC: Ethanolamine 
phosphorylceramide, EPCS: Ethanolamine phosphorylceramide synthase; EtN-P: 
ethanolamine phosphate. 
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6.4 Lipidomic analyses 
Lipids are the main building blocks of all cell membranes, in addition they serve as a 
source of energy and work as a signaling molecules within and between the cells. 
Furthermore, lipids anchor several proteins and glycoconjugates to the cell membrane 
(Tanowwitz et al., 2011, Ramakrishan et al., 2013). Intracellular pathogens such as the 
viruses, bacteria and protozoa (e.g. Leishmania spp.), may use host cell lipids as a source 
of energy or manipulate the host lipid biosynthesis for their own benefit (Ehrt, 2007). In 
contrast some lipids are synthesized by the pathogen itself, for example the 
glycosylphosphatidylinositol (GPI) lipids which anchor the lipophosphoglycans of 
Leishmania spp. to the cell surface and are essential for host specificity and parasite 
survival inside the sand fly (Dobson et al., 2010).  
To further enhance metabolomic results, lipidomic analyses have been performed to 
investigate mechanisms of drug resistance (Imbert et al., 2012), and to confirm the 
action of compounds on lipid metabolism (Creek and Barrett, 2013). Metabolomic 
analyses demonstrated that clemastine exerted the expected (and statistically 
significant) influence on the Leishmania metabolome. To further establish the effects of 
this compound lipid metabolism, cells were treated with different concentrations of 
clemastine for 42 hours (0.1, 0.5, 1, 5 and 10 µΜ) before microscopic analyses. Whilst 
significant cell death was seen at 10 µΜ, 5 µΜ was well tolerated with cells rounded but 
viable. Therefore, L. major promastigotes were incubated with 5 µΜ clemastine or the 
vehicle for 42 hours. Lipids were extracted and analysed by ES-MS and GC-MS as 
described in Materials and Methods. Focusing specifically on the inositol lipids, IPC can 
be quantified relative to PI. The results showed that the quantity of IPC (between m/z 
778.8-806.8) (Zhang et al., 2005) relative to PI is reduced in the treated samples (37.1%-
25.6%; Figure 6-4). This demonstrated that clemastine reduces IPC synthase, presumably 
through inhibition of IPCS. These data agreed with the previous metabolomic results 









Figure (6-4) Lipidomics analyses of Leishmania major promastigotes treated with 
vehicle (DMSO; A), or 5 µM clemastine (B) for 42 hours. IPC’s: inositol phosphoryl 































Chapter seven:  
An investigation of the mode of action 
of the anti-leishmanial miltefosine




Miltefosine or hexadecyl phosphate choline is an antitumor drug (Figure 7-1), which 
shows potent activity against Leishmania spp. Currently, it is the only oral drug for 
leishmaniasis and is now widely used in North-west India (Canuto et al., 2014). It has 
been demonstrated that the miltefosine changes the phospholipids and sterol 
composition in treated tumor cells (Geilen et al., 1996). Some studies suggested that the 
mechanism of action of the drug was related to the apoptotic process (Wright et al., 
2004; Sundar and Olliaro, 2007). More recently it was found that miltefosine caused a 
perturbation of the membrane lipids of axenic L. donovani amastigotes, decreasing the 
membrane PLs and amino acids pools, whilst SLs and sterols were increased (Armitage 
et al., 2017).    
In this study, the importance of SL synthesis in the mode of miltefosine action was 
investigated using L. major wild type promastigotes and  the transgenic strain lacking 
SLs, L. major ΔLCB2 (Denny et al, 2004). 
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7.2 Establishing the efficacy of miltefosine against wild type and ∆LCB2 
mutant Leishmania major 
The anti-leishmanial effect of miltefosine at various concentrations was established 
as described in Materials and Methods and the data used to calculate the EC50 of the 
drug against wild type and ∆LCB2. The efficacy of miltefosine was approximately 3-
fold lower in the mutant SL-free strain, EC50 21.2 µM (95% CI 20.1-22.3) versus 6.83 
µM (95% CI 6.1-7.6) in wild type promastigotes (Figure 7-2). This demonstrated that SL-
free mutant parasites are more resistant to miltefosine, indicating a role for SLs in the 
mode of action of miltefosine.  
Figure (7-2) Efficacy of miltefosine against wild type and ∆LCB2 Leishmania major. log 
(miltefosine; µM) vs % parasite proliferation. EC50 wild type (6.83 µM [95% CI 6.1-7.6]) 
and ∆LCB2 (21.2 µM [95% CI 20.1-22.3]) calculated in GraphPad Prism 7, normalised 









7.3 The effects of miltefosine on the Leishmania major wild type and 
∆LCB2 metabolomes  
Further analyses were performed, in collaboration with Emily Armitage and Mike 
Barrett (University of Glasgow), using a metabolomic approach. Two miltefosine 
concentrations (10 µM and 30 µM) were used to treat wild type and ∆LCB2 
promastogites and the metabolites extracted using a procedure optimised such that LC-
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MS and CE-MS analyses could be performed as described in Armitage et al. (2017). The 
LC-MS data allowed analyses of SLs, and the results showed a massive difference in the 
lipidome between the wild type and SL-free mutant promastigotes. As expected, due to 
the absence of a functional SPT (first enzyme in the biosynthetic pathway, most SLs were 
lacking in the mutant. The SLs that were detected, for instance sphinganine-1-
phosphate, sphingosine ceramide (d36:1) and sphingomyelin, were almost certainly 
obtained from the media.  
When treated with low (10 µM) and high dose (30 µM) miltefsoine, wild type L. major 
promastigote SL levels were increased dramatically, perhaps due to a stimulatory effect 
of the drug on the SL biosynthetic pathway or inhibition of the catabolic pathway (Figure 
7-3). The latter looks more likely as the ∆LCB2 mutant accumulate SLs from the media at 
a higher level upon treatment (figure 7-3). Together, these data suggest that SLs have a 
role in the sensitivity of Leishmania to miltefosine, and that the drug may have a direct 
effect on the parasite SL biosynthetic pathway.     
Figure (7-3) Fold change in abundance of all sphingolipids detected in LC-MS analyses 
of wild type and ∆LCB2 Leishmania major treated or un-treated with 10 μM or 30 μM 











Chapter eight:  
General discussion and Future Work




8.1 General Discussion  
Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis and 
belongs to the phylum apicomplexa. Although drugs are available to treat the acute 
toxoplasmosis, there are still none for chronic disease (Francia et al. 2016). In addition, 
the drugs used against T.  gondii are limited and cause many side effects (Palencia et al., 
2017). Therefore, there is a critical demand for new, less toxic, therapeutic agents, and 
by focusing on enzymes that are unique to the parasite the discovery of these may be 
accelerated (Palencia et al., 2017). Protozoan lipid biosynthesis, particularly of 
sphingolipids (Denny et al., 2006; Pratt et al., 2013), provides such new targets. This 
study investigated the potential of T. gondii serine palmitoyltransferase (TgSPT, the 
enzyme responsible for the first step in sphingolipid biosynthesis) as a drug target. In 
addition, using Leishmania major as a model, the effects of inhibiting inositol 
phosphorylceramide synthase (IPCS), an enzyme drug target found only in the parasite 
(Denny et al., 2006), was investigated. 
There are two potential SPTs encoded by T. gondii, TgSPT1 and TgSPT2 (68% identity), 
which were previously identified in ToxoDB (Mina et al., 2017). The available expression 
profiles (ToxoDB.org) of these genes in oocyst, tachyzoite and bradyzoite ME49 T. gondii 
was analysed in this study. The results showed that TgSPT1 is the predominantly 
expressed gene in tachyzoite T. gondii, whilst TgSPT2 is up regulated bradyzoites. Both 
TgSPT1 and SPT2 been suggested to be important for parasite fitness (Sidik et al., 2016). 
Previous studies have shown in eukaryotic organisms is found as a heterodimer has one 
active site in SPT2, whilst SPT1 lacking this active site and is thought to have a regulatory 
role (Hornemann et al., 2009). This enzyme is associated with membranes (Han et al., 
2004), whereas the prokaryotic SPT is cytoplasmic and forms a homodimer with two 
active sites (Ikushiro and Hayashi, 2001). Interestingly, bioinformatic analyses carried out 
in this study indicated that TgSPT1 and 2 is more closely related to the well-studied 
bacterial SPT from Gram negative Sphingomonas paucimobilis (SpSPT). The results 
showed that TgSPTs have 2 active sites, like the prokaryotic enzyme (Yard et al., 2007) 
and possess a potential transmembrane domain.  Biochemical assay carried out here 
confirmed TgSPT2 as a genuine serine palmitoyltransferase, like TgSPT1 (Mina et al., 




2017). In addition, like TgSPT1 and mammalian orthologues (Mina et al., 2017) it is 
located in the ER. An attempt at knocking out both TgSPT1 and 2 in this work was 
unsuccessful, indicating that the enzyme is essential.  Together, these findings 
demonstrate that whilst TgSPTs have a prokaryotic origin they have a eukaryotic 
function, and gene deletion attempts indicated that the enzyme is a potential drug 
target.  
In parallel, gene expression profiles of host SPT, and sphingomyelin synthase (SMS) 1 and 
2, were investigated to determine the role of host biosynthesis in T. gondii proliferation. 
Gene expression were unaffected by T. gondii infection, indicating that the parasite 
depends upon de novo sphingolipid biosynthesis.  Therefore, two antifungal IPCS 
inhibitors AbA and Cmpd20 (Wuts et al., 2015) were analysed against T. gondii 
tachyzoites and bradyzoites. As previously shown for AbA (Sonda et al., 2005), both 
compounds have an effect on parasite proliferation but not on host cells, with AbA 
showing higher efficacy. However, in contrast to previous reports (Sonda et al., 2005), 
neither compound inhibited sphingolipid biosynthesis. Therefore, this work did not 
chemically validate sphingolipid biosynthesis as a drug target, although the efficacy 
observed for both compounds against the chronic, bradyzoite stage may prove 
important (Antczak et al., 2016).  
To further investigate the role of IPCS in protozoan parasites, L. major promastigotes 
were used as a model to study metabolomic and lipidomic changes on inhibition of the 
enzyme. In-house developed inhibitors of L. major IPCS, for instance clemastine and 
benzazepine (Cmpd35) were utilised (Brown et al., submitted; Norcliffe et al, submitted). 
In addition, the oral antileishmanial drug miltefosine was investigated using similar 
approaches to determine its effects in sphingolipid biosynthesis (collaborative work with 
Emily Armitage and Mike Barrett [University of Glasgow]).  
Metabolomics is the quantitative measurement of the effect of a specific event (drug 
treatment, infection, etc; (Holmes et al., 2008). The effects of the two specific IPCS 
inhibitors against L. major were analysed using with the data showing that ceramide, a 
substrate for IPCS and a pro-apoptotic substance, accumulated in large amounts. More 
focused, lipidomic analyses, showed that IPC (the enzyme product) was dramatically 




decreased in clemastine treated parasites. These data confirmed that the sphingolipid 
biosynthetic pathway is targeted by these anti-leishmanial compounds. 
Finally, the anti-leishmanial drug miltefosine showed reduced activity against a 
transgenic strain of L. major lacking sphingolipid biosynthesis (ΔLCB2; Denny et al., 2004) 
compared to wild type. This suggested the sphingolipid synthesis has a role in sensitivity 
to the drug, metabolomic analyses supported this, agreeing with previous studies 
(Rybczynska et al., 2001; Wright et al., 2004). 
Taken together, the present findings further characterised the T. gondii sphingolipid 
biosynthetic pathway and indicated the potential to target this in drug discovery efforts. 
In addition, metabolomic and lipidomic approaches confirmed that clemastine targets L. 























8.2 Future work 
As the importance of sphingolipid biosynthesis pathway in this parasite, more study is 
required to detect the possible drug target in this pathway focusing on the enzymes that 
responsible to produce an important sphingolipids for instance ceramide synthase which 
responsible to form the ceramide.  
 
Since one of the outcomes of this study showed that both TgSPT1 and TgSPT2 are 
important for parasite proliferation, the efforts to make a mutant parasite lacking either 
TgSPT1 or TgSPt2 or both are required to show the importance of both enzymes in acute 
and chronic toxoplasmosis by using CRISPR-Cas9.Furthermore, the metabolomics 
analysis will be crucial to study the global effects of these knockouts on T. gondii, taking 
into account modifying the metabolomic procedure to avoid the host contaminants. 
 
This study showed that both AbA and its analogue CMPD20 were active against the 
parasite, however the sphingolipid biosynthesis is not the drug target, so more analysis 
needs to show the mode of action of AbA and its analogues against T. gondii tachyzoites 
and bradyzoites by using metabolomic analysis. 
 
Further studies should investigate the mode of clemastine action in axenic amastigote 
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